{"items": "102", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2024/12/23/3001187/0/en/Replimune-to-Present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20241223T130000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Dec. 23, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 43rd Annual J.P.", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002464, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.633079", "ticker_sentiment_score": "-0.074325", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Pricing of Upsized Public Offering", "url": "https://www.globenewswire.com/news-release/2024/11/26/2987176/0/en/Replimune-Announces-Pricing-of-Upsized-Public-Offering.html", "time_published": "20241126T045500", "authors": ["Replimune Group Inc"], "summary": "BOSTON, Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of its public offering of 6,923,000 shares of its common stock at a public ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.9545"}, {"topic": "Financial Markets", "relevance_score": "0.996718"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.040574, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.426464", "ticker_sentiment_score": "0.106855", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.044885", "ticker_sentiment_score": "0.045013", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Proposed Public Offering", "url": "https://www.globenewswire.com/news-release/2024/11/25/2986558/0/en/Replimune-Announces-Proposed-Public-Offering.html", "time_published": "20241125T120900", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Nov. 25, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.045382, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.416844", "ticker_sentiment_score": "0.060058", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.048621", "ticker_sentiment_score": "0.048392", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results - Aptose Biosciences  ( NASDAQ:APTO ) , Autonomix Medical  ( NASDAQ:AMIX ) ", "url": "https://www.benzinga.com/24/11/42145950/s-intuit-shares-fall-following-q1-results", "time_published": "20241122T191842", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining by more than 350 points on Friday. The Dow traded up 0.82% to 44,228.50 while the NASDAQ rose 0.14% to 18,998.27. The S&P 500 also rose, gaining, 0.31% to 5,966.91. Consumer staples shares rose by 1.5% on Friday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/22/Intuit-Sign-Is-Displayed-Near-Business-A_1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.904684"}], "overall_sentiment_score": 0.222079, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APTO", "relevance_score": "0.151064", "ticker_sentiment_score": "0.126169", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTU", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.094556", "ticker_sentiment_label": "Neutral"}, {"ticker": "MATW", "relevance_score": "0.151064", "ticker_sentiment_score": "0.522347", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMIX", "relevance_score": "0.151064", "ticker_sentiment_score": "0.132573", "ticker_sentiment_label": "Neutral"}, {"ticker": "CETX", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.046756", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.151064", "ticker_sentiment_score": "0.321106", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.151064", "ticker_sentiment_score": "-0.018115", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESTC", "relevance_score": "0.151064", "ticker_sentiment_score": "0.382174", "ticker_sentiment_label": "Bullish"}]}, {"title": "Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Aptose Biosciences  ( NASDAQ:APTO ) , Autonomix Medical  ( NASDAQ:AMIX ) ", "url": "https://www.benzinga.com/24/11/42144711/crude-oil-gains-over-1-ross-stores-earnings-top-views", "time_published": "20241122T181656", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining by more than 250 points on Friday. The Dow traded up 0.59% to 44,128.84 while the NASDAQ rose 0.08% to 18,986.80. The S&P 500 also rose, gaining, 0.28% to 5,965.15. Consumer staples shares rose by 1.5% on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/22/oil-prices-5079975.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.255625, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "APTO", "relevance_score": "0.163354", "ticker_sentiment_score": "0.132528", "ticker_sentiment_label": "Neutral"}, {"ticker": "MATW", "relevance_score": "0.163354", "ticker_sentiment_score": "0.542726", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMIX", "relevance_score": "0.163354", "ticker_sentiment_score": "0.139247", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROST", "relevance_score": "0.163354", "ticker_sentiment_score": "0.521494", "ticker_sentiment_label": "Bullish"}, {"ticker": "CETX", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.049238", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.163354", "ticker_sentiment_score": "0.336138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.163354", "ticker_sentiment_score": "-0.01905", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESTC", "relevance_score": "0.163354", "ticker_sentiment_score": "0.399332", "ticker_sentiment_label": "Bullish"}]}, {"title": "Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug", "url": "https://www.zacks.com/stock/news/2374136/replimune-stock-rallies-on-bla-filing-for-melanoma-combo-drug", "time_published": "20241122T162300", "authors": ["Zacks Equity Research"], "summary": "REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/39/612.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.138426, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALLO", "relevance_score": "0.22616", "ticker_sentiment_score": "0.078711", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.395012", "ticker_sentiment_score": "0.278236", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PFE", "relevance_score": "0.136888", "ticker_sentiment_score": "0.099096", "ticker_sentiment_label": "Neutral"}]}, {"title": "Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday - Atkore  ( NYSE:ATKR ) , Carpenter Tech  ( NYSE:CRS ) ", "url": "https://www.benzinga.com/24/11/42141440/natural-grocers-by-vitamin-cottage-elastic-matthews-international-gap-and-other-big-stocks-moving-higher-on-frida", "time_published": "20241122T155904", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday. Shares of Natural Grocers by Vitamin Cottage, Inc. NGVC rose sharply during Friday's session following quarterly results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/22/movers-image.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.448974, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "NGVC", "relevance_score": "0.324495", "ticker_sentiment_score": "0.243988", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVTS", "relevance_score": "0.219809", "ticker_sentiment_score": "0.537609", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRS", "relevance_score": "0.219809", "ticker_sentiment_score": "0.145677", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.219809", "ticker_sentiment_score": "0.537609", "ticker_sentiment_label": "Bullish"}, {"ticker": "REPL", "relevance_score": "0.219809", "ticker_sentiment_score": "0.352003", "ticker_sentiment_label": "Bullish"}, {"ticker": "PSNY", "relevance_score": "0.219809", "ticker_sentiment_score": "0.432666", "ticker_sentiment_label": "Bullish"}, {"ticker": "OMER", "relevance_score": "0.219809", "ticker_sentiment_score": "0.432666", "ticker_sentiment_label": "Bullish"}, {"ticker": "PTGX", "relevance_score": "0.219809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOUN", "relevance_score": "0.219809", "ticker_sentiment_score": "0.432666", "ticker_sentiment_label": "Bullish"}, {"ticker": "MATW", "relevance_score": "0.219809", "ticker_sentiment_score": "0.440058", "ticker_sentiment_label": "Bullish"}, {"ticker": "QBTS", "relevance_score": "0.219809", "ticker_sentiment_score": "0.245082", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GAP", "relevance_score": "0.219809", "ticker_sentiment_score": "0.405731", "ticker_sentiment_label": "Bullish"}, {"ticker": "VSAT", "relevance_score": "0.219809", "ticker_sentiment_score": "0.537609", "ticker_sentiment_label": "Bullish"}, {"ticker": "WOLF", "relevance_score": "0.219809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESTC", "relevance_score": "0.219809", "ticker_sentiment_score": "0.529476", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Jumps 300 Points; Gap Posts Upbeat Earnings - Aptose Biosciences  ( NASDAQ:APTO ) , Autonomix Medical  ( NASDAQ:AMIX ) ", "url": "https://www.benzinga.com/24/11/42140418/dow-jumps-300-points-gap-posts-upbeat-earnings", "time_published": "20241122T152320", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Friday. Following the market opening Friday, the Dow traded up 0.72% to 44,184.62 while the NASDAQ rose 0.07% to 18,985.33. The S&P 500 also rose, gaining, 0.35% to 5,969.29.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/22/Wall-Street-US-stocks.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.190418, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DEVS", "relevance_score": "0.16171", "ticker_sentiment_score": "0.461994", "ticker_sentiment_label": "Bullish"}, {"ticker": "SKK", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.204232", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "APTO", "relevance_score": "0.16171", "ticker_sentiment_score": "0.131658", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMIX", "relevance_score": "0.16171", "ticker_sentiment_score": "0.138334", "ticker_sentiment_label": "Neutral"}, {"ticker": "GAP", "relevance_score": "0.16171", "ticker_sentiment_score": "0.059851", "ticker_sentiment_label": "Neutral"}, {"ticker": "CETX", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.048901", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.16171", "ticker_sentiment_score": "0.334094", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPGI", "relevance_score": "0.16171", "ticker_sentiment_score": "-0.018922", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/24/11/g42123154/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-rp1-biologics-license-appl", "time_published": "20241121T210500", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Nov. 21, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.050945, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.33433", "ticker_sentiment_score": "0.06647", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer  ( SITC 2024 ) ", "url": "https://www.globenewswire.com/news-release/2024/11/09/2977965/0/en/Replimune-Presents-Late-Breaking-Abstract-Featuring-Data-from-IGNYTE-Clinical-Trial-of-RP1-Combined-with-Nivolumab-in-Anti-PD1-Failed-Melanoma-at-the-39th-Annual-Meeting-of-the-Soc.html", "time_published": "20241109T180000", "authors": ["Replimune Group Inc"], "summary": "Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration, and kinetics ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.01688, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.122269", "ticker_sentiment_score": "0.001202", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer  ( SITC )  - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/24/10/g41624859/replimune-to-present-at-the-39th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc", "time_published": "20241030T131509", "authors": ["Globe Newswire"], "summary": "Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.031403, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.240965", "ticker_sentiment_score": "-0.019237", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer  ( SITC ) ", "url": "https://www.globenewswire.com/news-release/2024/10/30/2971775/0/en/Replimune-to-Present-at-the-39th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html", "time_published": "20241030T131500", "authors": ["Replimune Group Inc"], "summary": "Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.002425, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.165788", "ticker_sentiment_score": "-0.014554", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology  ( ESMO )  Congress 2024", "url": "https://www.globenewswire.com/news-release/2024/09/15/2946296/0/en/Replimune-Presents-Primary-Analysis-Data-from-IGNYTE-Clinical-Trial-of-RP1-Combined-with-Nivolumab-in-Anti-PD1-Failed-Melanoma-at-European-Society-for-Medical-Oncology-ESMO-Congres.html", "time_published": "20240915T134500", "authors": ["Replimune Group Inc"], "summary": "Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary resistance to ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.043436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.145364", "ticker_sentiment_score": "0.03181", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stockholders Vote to Elect Madhavan Balachandran to Board of Directors - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/24/09/g40727738/stockholders-vote-to-elect-madhavan-balachandran-to-board-of-directors", "time_published": "20240905T120000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Sept. 05, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Madhavan ( Madhu ) Balachandran was elected to Replimune's Board of Directors at ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.089164, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.096283", "ticker_sentiment_score": "-0.034603", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.532043", "ticker_sentiment_score": "0.130849", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology  ( ESMO )  Congress 2024 - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/24/08/g40504664/replimune-announces-late-breaking-abstract-of-ignyte-clinical-trial-primary-analysis-selected-for-", "time_published": "20240822T120000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Aug. 22, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": -0.014561, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.268", "ticker_sentiment_score": "-0.035357", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma", "url": "https://www.globenewswire.com/news-release/2024/08/13/2929115/0/en/Replimune-Announces-First-Patient-Dosed-in-IGNYTE-3-Clinical-Trial-in-Advanced-Melanoma.html", "time_published": "20240813T120000", "authors": ["Replimune Group Inc"], "summary": "Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 ( vusolimogene oderparepvec ) in combination with nivolumab in patients with advanced melanoma Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.082347, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.173645", "ticker_sentiment_score": "0.053617", "ticker_sentiment_label": "Neutral"}]}, {"title": "Anaveon appoints Dieter Weinand as Chair of its Board of Directors", "url": "https://www.benzinga.com/pressreleases/24/07/g40028529/anaveon-appoints-dieter-weinand-as-chair-of-its-board-of-directors", "time_published": "20240730T060000", "authors": ["Globe Newswire"], "summary": "BASEL, Switzerland, July 30, 2024 ( GLOBE NEWSWIRE ) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer Pharmaceuticals, as Chair of its Board of Directors.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.254198, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.179121", "ticker_sentiment_score": "0.053275", "ticker_sentiment_label": "Neutral"}, {"ticker": "JWCTF", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.090134", "ticker_sentiment_score": "0.038482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.090134", "ticker_sentiment_score": "0.038482", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.090134", "ticker_sentiment_score": "0.038482", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune  ( REPL )  Gains on Positive Data From Melanoma Study", "url": "https://www.zacks.com/stock/news/2285366/replimune-repl-gains-on-positive-data-from-melanoma-study", "time_published": "20240607T130300", "authors": ["Zacks Equity Research"], "summary": "Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default243.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.038546, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALXO", "relevance_score": "0.163539", "ticker_sentiment_score": "-0.012488", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.320279", "ticker_sentiment_score": "0.164975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KRYS", "relevance_score": "0.269181", "ticker_sentiment_score": "0.099171", "ticker_sentiment_label": "Neutral"}]}, {"title": "Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Vail Resorts  ( NYSE:MTN ) ", "url": "https://www.benzinga.com/news/24/06/39225632/vail-resorts-posts-downbeat-q3-results-joins-concrete-pumping-docusign-and-other-big-stocks-moving-l", "time_published": "20240607T122235", "authors": ["Avi Kapoor"], "summary": "U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Vail Resorts, Inc. MTN fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its third quarter.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/07/Image22.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}, {"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.075868, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BBCP", "relevance_score": "0.21686", "ticker_sentiment_score": "0.223178", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FTEL", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.110632", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTN", "relevance_score": "0.320279", "ticker_sentiment_score": "-0.237168", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EBC", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.110632", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMEA", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.043044", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.320279", "ticker_sentiment_score": "-0.095183", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.320279", "ticker_sentiment_score": "0.221426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IOT", "relevance_score": "0.21686", "ticker_sentiment_score": "-0.072956", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2024/06/07/2895328/0/en/Replimune-to-Present-at-the-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html", "time_published": "20240607T120000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., June 07, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Sushil Patel, Chief Executive Officer of Replimune, will present at ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.002458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.172097", "ticker_sentiment_score": "0.05804", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.615462", "ticker_sentiment_score": "-0.069532", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings - Lululemon Athletica  ( NASDAQ:LULU ) ", "url": "https://www.benzinga.com/news/24/06/39211280/crude-oil-jumps-2-lululemon-posts-upbeat-earnings", "time_published": "20240606T162251", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday. The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 500 also rose, gaining, 0.01% to 5,354.33. Consumer discretionary shares rose by 0.5% on Thursday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/Saudi-Arabia--Russia--Usa-Oil-Price-War-.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.185253, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "LULU", "relevance_score": "0.112008", "ticker_sentiment_score": "0.223716", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VTYX", "relevance_score": "0.112008", "ticker_sentiment_score": "-0.12353", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRGT", "relevance_score": "0.112008", "ticker_sentiment_score": "0.198074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASNS", "relevance_score": "0.112008", "ticker_sentiment_score": "0.265067", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.112008", "ticker_sentiment_score": "0.073533", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.056143", "ticker_sentiment_score": "-0.02", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICU", "relevance_score": "0.167322", "ticker_sentiment_score": "0.016049", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.112008", "ticker_sentiment_score": "0.201418", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/general/biotech/24/06/39211109/why-is-mid-cap-cancer-focused-replimune-stock-trading-higher-on-thursday", "time_published": "20240606T161620", "authors": ["Vandana Singh"], "summary": "Thursday, Replimune Group Inc REPL released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co's BMY Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat several types ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/REPL.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.100026, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.342487", "ticker_sentiment_score": "-0.066125", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.232439", "ticker_sentiment_score": "-0.123045", "ticker_sentiment_label": "Neutral"}]}, {"title": "J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday - JM Smucker  ( NYSE:SJM ) ", "url": "https://www.benzinga.com/news/24/06/39208649/j-m-smuckerposts-upbeat-earnings-joins-toro-company-united-natural-foods-semtech-and-other-big-stock", "time_published": "20240606T144448", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of The J. M. Smucker Company SJM rose sharply during Thursday's session following upbeat quarterly earnings.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/06/06/xrdDAFlBgQqXKI2-j3472667867116897537-t23.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.947132"}], "overall_sentiment_score": 0.344435, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "TTC", "relevance_score": "0.178459", "ticker_sentiment_score": "0.44591", "ticker_sentiment_label": "Bullish"}, {"ticker": "ILMN", "relevance_score": "0.178459", "ticker_sentiment_score": "0.474279", "ticker_sentiment_label": "Bullish"}, {"ticker": "XPOF", "relevance_score": "0.178459", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.178459", "ticker_sentiment_score": "0.01206", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.178459", "ticker_sentiment_score": "0.322381", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMTC", "relevance_score": "0.178459", "ticker_sentiment_score": "0.332014", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CIEN", "relevance_score": "0.178459", "ticker_sentiment_score": "0.352543", "ticker_sentiment_label": "Bullish"}, {"ticker": "LULU", "relevance_score": "0.178459", "ticker_sentiment_score": "0.403771", "ticker_sentiment_label": "Bullish"}, {"ticker": "SCWX", "relevance_score": "0.178459", "ticker_sentiment_score": "0.560801", "ticker_sentiment_label": "Bullish"}, {"ticker": "IRTC", "relevance_score": "0.178459", "ticker_sentiment_score": "0.474279", "ticker_sentiment_label": "Bullish"}, {"ticker": "UNFI", "relevance_score": "0.264897", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HALO", "relevance_score": "0.178459", "ticker_sentiment_score": "0.203322", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOD", "relevance_score": "0.178459", "ticker_sentiment_score": "0.17208", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CART", "relevance_score": "0.178459", "ticker_sentiment_score": "0.370201", "ticker_sentiment_label": "Bullish"}]}, {"title": "Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma", "url": "https://www.globenewswire.com/news-release/2024/06/06/2894545/0/en/Replimune-Announces-Positive-Topline-Primary-Analysis-Data-by-Independent-Central-Review-from-IGNYTE-Clinical-Trial-of-RP1-plus-Nivolumab-in-Anti-PD1-Failed-Melanoma.html", "time_published": "20240606T110000", "authors": ["Replimune Group Inc"], "summary": "Primary endpoint data shows 12-month overall response rate ( ORR ) of ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.02661, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.179254", "ticker_sentiment_score": "0.054168", "ticker_sentiment_label": "Neutral"}]}, {"title": "CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors - Cargo Therapeutics  ( NASDAQ:CRGX ) ", "url": "https://www.benzinga.com/pressreleases/24/04/g38258186/cargo-therapeutics-names-kapil-dhingra-m-b-b-s-to-board-of-directors", "time_published": "20240415T200500", "authors": ["Globe Newswire"], "summary": "SAN MATEO, Calif., April 15, 2024 ( GLOBE NEWSWIRE ) -- CARGO Therapeutics, Inc. CRGX, a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company's ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}], "overall_sentiment_score": 0.109403, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AUTL", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRGNF", "relevance_score": "0.033846", "ticker_sentiment_score": "0.01176", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDTX", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.033846", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRGX", "relevance_score": "0.233556", "ticker_sentiment_score": "0.123569", "ticker_sentiment_label": "Neutral"}]}, {"title": "Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research  ( AACR )  2024 Annual Meeting", "url": "https://www.globenewswire.com/news-release/2024/04/07/2858850/0/en/Interim-Results-from-the-ARTACUS-Clinical-Trial-of-RP1-Monotherapy-in-Solid-Organ-and-Hematopoietic-Cell-Transplant-Recipients-with-Skin-Cancers-Presented-During-Oral-Presentation-.html", "time_published": "20240407T210000", "authors": ["Replimune Group Inc"], "summary": "RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.048507, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.206862", "ticker_sentiment_score": "0.053989", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions", "url": "https://www.globenewswire.com/news-release/2024/03/26/2852257/0/en/Replimune-Announces-Appointment-of-Sushil-Patel-to-CEO-and-Executive-Leadership-Transitions.html", "time_published": "20240326T113000", "authors": ["Replimune Group Inc"], "summary": "Philip Astley-Sparke to transition from current role of CEO to Executive Chairman ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.102628, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.332261", "ticker_sentiment_score": "0.144116", "ticker_sentiment_label": "Neutral"}]}, {"title": "How Much Upside is Left in Replimune Group, Inc.  ( REPL ) ? Wall Street Analysts Think 50.17%", "url": "https://www.zacks.com/stock/news/2238679/how-much-upside-is-left-in-replimune-group-inc-repl-wall-street-analysts-think-5017", "time_published": "20240311T135506", "authors": ["Zacks Equity Research"], "summary": "The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default247.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.233307, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.283542", "ticker_sentiment_score": "0.30299", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What Makes Replimune Group, Inc.  ( REPL )  a New Buy Stock", "url": "https://www.zacks.com/stock/news/2238210/what-makes-replimune-group-inc-repl-a-new-buy-stock", "time_published": "20240308T170008", "authors": ["Zacks Equity Research"], "summary": "Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default60.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.307926, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.357293", "ticker_sentiment_score": "0.309578", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc.  ( REPL ) : Can the Stock Really Move This High?", "url": "https://www.zacks.com/stock/news/2230991/wall-street-analysts-see-a-7057-upside-in-replimune-group-inc-repl-can-the-stock-really-move-this-high", "time_published": "20240223T145506", "authors": ["Zacks Equity Research"], "summary": "The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.215802, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.283542", "ticker_sentiment_score": "0.30299", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Oncolytic Virus Immunotherapy Market Expected to Reach USD 572.2 million by 2031, Expanding at a 21.1% CAGR | Transparency Market Research, Inc.", "url": "https://www.benzinga.com/pressreleases/24/02/g37231570/oncolytic-virus-immunotherapy-market-expected-to-reach-usd-572-2-million-by-2031-expanding-at-a-21", "time_published": "20240221T110718", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, Feb. 21, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global oncolytic virus immunotherapy market was projected to attain US$ 110.2 million in 2022.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.017107, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ONCY", "relevance_score": "0.037622", "ticker_sentiment_score": "-0.075796", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOG", "relevance_score": "0.037622", "ticker_sentiment_score": "0.050656", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIGA", "relevance_score": "0.037622", "ticker_sentiment_score": "-0.075796", "ticker_sentiment_label": "Neutral"}, {"ticker": "CADL", "relevance_score": "0.075161", "ticker_sentiment_score": "0.121248", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.037622", "ticker_sentiment_score": "-0.075796", "ticker_sentiment_label": "Neutral"}, {"ticker": "WMGTF", "relevance_score": "0.112532", "ticker_sentiment_score": "0.027885", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBIO", "relevance_score": "0.037622", "ticker_sentiment_score": "0.09341", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update", "url": "https://www.globenewswire.com/news-release/2024/02/08/2825950/0/en/Replimune-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html", "time_published": "20240208T130000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}], "overall_sentiment_score": -0.021684, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.088066", "ticker_sentiment_score": "0.014749", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/23/12/g36409717/replimune-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference", "time_published": "20231228T130000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Dec. 28, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 42nd ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002436, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.730535", "ticker_sentiment_score": "-0.067094", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2023/12/28/2801681/0/en/Replimune-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20231228T130000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Dec. 28, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002452, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.598621", "ticker_sentiment_score": "-0.06483", "ticker_sentiment_label": "Neutral"}]}, {"title": "Massachusetts Biotech Plummets as Skin Cancer Trial Fails", "url": "https://www.investorideas.com/news/2023/biotech/12061Massachusetts-Biotech.asp", "time_published": "20231206T192647", "authors": [], "summary": "December 6, 2023 ( Investorideas.com Newswire ) In recent news, Massachusetts clinical-stage biotechnology company Replimune Group Inc. revealed its latest clinical trial did not meet the endpoints needed to call it a success. With this, the stock has plummeted.", "banner_image": "https://www.streetwisereports.com/images/national-cancer-institute-I_i2GI8e1_o-unsplash_2.jpg", "source": "Investor Ideas", "category_within_source": "n/a", "source_domain": "www.investorideas.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.036457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WBD", "relevance_score": "0.057215", "ticker_sentiment_score": "0.005", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.649187", "ticker_sentiment_score": "0.041142", "ticker_sentiment_label": "Neutral"}]}, {"title": "Crude Oil Moves Lower; AutoZone Profit Tops Views - AutoZone  ( NYSE:AZO ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36099575/crude-oil-moves-lower-autozone-profit-tops-views", "time_published": "20231205T192749", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500 also fell, dropping, 0.07% to 4,566.73. Information technology shares rose by 0.4% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/image44.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.023877, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.119235", "ticker_sentiment_score": "0.22121", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AZO", "relevance_score": "0.119235", "ticker_sentiment_score": "0.324864", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.119235", "ticker_sentiment_score": "0.01853", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.235823", "ticker_sentiment_score": "-0.059756", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBI", "relevance_score": "0.119235", "ticker_sentiment_score": "-0.054212", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFH", "relevance_score": "0.119235", "ticker_sentiment_score": "0.25772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMND", "relevance_score": "0.119235", "ticker_sentiment_score": "0.129998", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Falls 100 Points; ISM Services PMI Increases In November - Allarity Therapeutics  ( NASDAQ:ALLR ) , Clearmind Medicine  ( NASDAQ:CMND ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36097189/dow-falls-100-points-ism-services-pmi-increases-in-november", "time_published": "20231205T171148", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P 500 also fell, dropping, 0.03% to 4,568.46. Consumer discretionary shares rose by 0.7% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/image47.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.021511, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.126784", "ticker_sentiment_score": "0.019075", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.250386", "ticker_sentiment_score": "-0.062748", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBI", "relevance_score": "0.126784", "ticker_sentiment_score": "-0.055857", "ticker_sentiment_label": "Neutral"}, {"ticker": "MFH", "relevance_score": "0.126784", "ticker_sentiment_score": "0.264621", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALLR", "relevance_score": "0.126784", "ticker_sentiment_score": "0.072664", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMND", "relevance_score": "0.126784", "ticker_sentiment_score": "0.133564", "ticker_sentiment_label": "Neutral"}]}, {"title": "US Stocks Down; JM Smucker Posts Upbeat Earnings - Designer Brands  ( NYSE:DBI ) , Allarity Therapeutics  ( NASDAQ:ALLR ) ", "url": "https://www.benzinga.com/news/earnings/23/12/36093288/us-stocks-down-jm-smucker-posts-upbeat-earnings", "time_published": "20231205T143945", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell 0.40% to 14,129.09. The S&P 500 also fell, dropping, 0.30% to 4,556.06.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/image33.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": -0.050298, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.129168", "ticker_sentiment_score": "0.019255", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.192694", "ticker_sentiment_score": "-0.056977", "ticker_sentiment_label": "Neutral"}, {"ticker": "WNW", "relevance_score": "0.129168", "ticker_sentiment_score": "0.263772", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBI", "relevance_score": "0.129168", "ticker_sentiment_score": "-0.056398", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLR", "relevance_score": "0.129168", "ticker_sentiment_score": "0.073379", "ticker_sentiment_label": "Neutral"}]}, {"title": "What's Going On With Cancer-Focused Replimune Stock Today? - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36088337/whats-going-on-with-cancer-focused-replimune-stock-today", "time_published": "20231205T134955", "authors": ["Vandana Singh"], "summary": "Replimune Group Inc REPL announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous squamous cell carcinoma ( CSCC ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/05/repl.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": -0.009527, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.359014", "ticker_sentiment_score": "0.205422", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune's skin cancer drug fails in mid-stage study", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/replimunes-skin-cancer-drug-fails-mid-stage-study-2023-12-05/", "time_published": "20231205T124300", "authors": ["Reuters"], "summary": "Dec 5 ( Reuters ) - Replimune Group ( REPL.O ) said on Tuesday its experimental drug to treat a common form of skin cancer did not meet the main goals in a mid-stage study. The therapy, RP1, in combination with cemiplimab failed to significantly remove or reduce cancerous lesions in patients ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.webp?d=165", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.278548, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.504646", "ticker_sentiment_score": "-0.161068", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers", "url": "https://www.globenewswire.com/news-release/2023/12/05/2790782/0/en/Replimune-Shares-Initial-Primary-Analysis-Results-from-CERPASS-Clinical-Trial-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma-and-Presents-New-Data-from-IGNYTE-Clinical-Trial-of-RP1-.html", "time_published": "20231205T120000", "authors": ["Replimune Group Inc"], "summary": "RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": -0.01217, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REGN", "relevance_score": "0.016691", "ticker_sentiment_score": "0.163105", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.083309", "ticker_sentiment_score": "0.023136", "ticker_sentiment_label": "Neutral"}]}, {"title": "GMAB: 3 Biotech Stocks Flowing With Investment Potential", "url": "https://stocknews.com/news/gmab-incy-orgo-3-biotech-stocks-flowing-with-investment-potential/", "time_published": "20231124T152440", "authors": ["StockNews.com Staff"], "summary": "Despite broader economic challenges, the biotech industry thrives due to consistent innovation and steady demand. An aging population and the need for high-quality treatments for rare and common diseases back the optimism surrounding the industry.", "banner_image": "https://stocknews.com/wp-content/uploads/2023/07/ABhuyan.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.503496"}], "overall_sentiment_score": 0.286985, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.196725", "ticker_sentiment_score": "0.21808", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.085022", "ticker_sentiment_score": "0.078513", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.304542", "ticker_sentiment_score": "0.085746", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORGO", "relevance_score": "0.085022", "ticker_sentiment_score": "0.231374", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Forbion co-leads \u20ac129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023 - enGene Holdings  ( NASDAQ:ENGN ) , NewAmsterdam Pharma  ( NASDAQ:NAMS ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35751332/forbion-co-leads-129-million-series-a-financing-of-vectory-one-of-the-largest-private-biotech-fina", "time_published": "20231113T145543", "authors": ["Globe Newswire"], "summary": "Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis ( ALS ) and additional pipeline programs", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.267147, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ENGN", "relevance_score": "0.083541", "ticker_sentiment_score": "0.177452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NAMS", "relevance_score": "0.083541", "ticker_sentiment_score": "0.177452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.083541", "ticker_sentiment_score": "0.177452", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research", "url": "https://www.globenewswire.com/news-release/2023/11/08/2776369/0/en/Replimune-Presents-Updated-Data-on-RP2-in-Uveal-Melanoma-during-Plenary-Session-at-the-20th-International-Congress-of-the-Society-for-Melanoma-Research.html", "time_published": "20231108T141000", "authors": ["Replimune Group Inc"], "summary": "RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.576289"}], "overall_sentiment_score": 0.009668, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.141726", "ticker_sentiment_score": "0.012943", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer  ( SITC ) ", "url": "https://www.globenewswire.com/news-release/2023/11/03/2773500/0/en/Replimune-Presents-Updated-Interim-Results-from-the-ARTACUS-Clinical-Trial-of-RP1-Monotherapy-in-Solid-Organ-and-Hematopoietic-Cell-Transplant-Recipients-with-Skin-Cancers-During-O.html", "time_published": "20231103T233000", "authors": ["Replimune Group Inc"], "summary": "RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.03647, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.206509", "ticker_sentiment_score": "0.035518", "ticker_sentiment_label": "Neutral"}]}, {"title": "INCY: 3 Revolutionary Biotech Stocks Worth Investing In", "url": "https://stocknews.com/news/incy-plx-eq-repl-sndx-3-revolutionary-biotech-stocks-worth-investing-in/", "time_published": "20231018T173032", "authors": ["StockNews.com Staff"], "summary": "The biotech industry's soaring growth owes much to the flourishing realm of personalized medicine, the rise of orphan drugs, innovative biotech tools, and unwavering government support.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/03/shutterstock_517925923-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.99999"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.998356"}], "overall_sentiment_score": 0.327132, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "INCY", "relevance_score": "0.247278", "ticker_sentiment_score": "0.232779", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.055816", "ticker_sentiment_score": "0.103", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.055816", "ticker_sentiment_score": "0.147043", "ticker_sentiment_label": "Neutral"}, {"ticker": "EQ", "relevance_score": "0.16636", "ticker_sentiment_score": "0.265897", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte", "url": "https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html", "time_published": "20230918T210100", "authors": ["DelveInsight Business Research", "LLP"], "summary": "Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.109459, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GLTO", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPHA", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGNE", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUSN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKUNF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.04824", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKESF", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXEL", "relevance_score": "0.046273", "ticker_sentiment_score": "0.058004", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOBT", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.069361", "ticker_sentiment_score": "0.052186", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGEN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBTX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "REGN", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCNX", "relevance_score": "0.023146", "ticker_sentiment_score": "0.04357", "ticker_sentiment_label": "Neutral"}]}, {"title": "Forbion co-leads $175 million Series B financing of Mariana Oncology as first investment of Forbion Ventures Fund VI - Replimune Group  ( NASDAQ:REPL ) , NewAmsterdam Pharma  ( NASDAQ:NAMS ) ", "url": "https://www.benzinga.com/pressreleases/23/09/g34310858/forbion-co-leads-175-million-series-b-financing-of-mariana-oncology-as-first-investment-of-forbion", "time_published": "20230907T104500", "authors": ["Globe Newswire"], "summary": "Forbion co-leads oversubscribed Series B financing in next-generation radiopharmaceuticals company First investment by its Forbion Ventures Fund VI, aimed at advancing highly impactful development-stage therapeutics companies", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.283302, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "NAMS", "relevance_score": "0.083541", "ticker_sentiment_score": "0.179516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.083541", "ticker_sentiment_score": "0.179516", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Is Incyte  ( INCY )  Down 0.7% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2143111/why-is-incyte-incy-down-07-since-last-earnings-report", "time_published": "20230831T153128", "authors": ["Zacks Equity Research"], "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default332.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.976671"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.149755, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BMRN", "relevance_score": "0.039679", "ticker_sentiment_score": "0.057849", "ticker_sentiment_label": "Neutral"}, {"ticker": "LLY", "relevance_score": "0.079261", "ticker_sentiment_score": "0.126034", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.482217", "ticker_sentiment_score": "0.221574", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.079261", "ticker_sentiment_score": "0.141818", "ticker_sentiment_label": "Neutral"}]}, {"title": "AMGN: 3 Best Biotech Stocks for Health and Wealth", "url": "https://stocknews.com/news/amgn-vrtx-incy-repl-sndx-3-best-biotech-stocks-for-health-and-wealth/", "time_published": "20230829T175651", "authors": ["StockNews.com Staff"], "summary": "Innovative biotech companies are making remarkable progress in creating novel medications and therapies for a diverse array of conditions, such as cancer, heart disease, and rare ailments. Encouraging trial outcomes and enhanced patient well-being are spurring the demand for continuous medical ...", "banner_image": "https://stocknews.com/wp-content/uploads/2023/01/ISt_Biotechnology.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999995"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.33801, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.141034", "ticker_sentiment_score": "0.136199", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.164228", "ticker_sentiment_score": "0.13575", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.047231", "ticker_sentiment_score": "0.108521", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDX", "relevance_score": "0.047231", "ticker_sentiment_score": "0.026781", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMGN", "relevance_score": "0.232885", "ticker_sentiment_score": "0.232763", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Incyte  ( INCY )  Beats on Q2 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2130522/incyte-incy-beats-on-q2-earnings-and-revenue-estimates", "time_published": "20230801T140500", "authors": ["Zacks Equity Research"], "summary": "Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.145466, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LLY", "relevance_score": "0.206685", "ticker_sentiment_score": "0.055609", "ticker_sentiment_label": "Neutral"}, {"ticker": "INCY", "relevance_score": "0.605524", "ticker_sentiment_score": "0.181687", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.155786", "ticker_sentiment_score": "0.170522", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune Group Getting Closer To Key Technical Benchmark", "url": "https://www.investors.com/ibd-data-stories/replimune-group-getting-closer-to-key-technical-benchmark-2/", "time_published": "20230719T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "The Relative Strength ( RS ) Rating for Replimune Group ( REPL ) headed into a higher percentile Wednesday, as it got a lift from 69 to 75. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.303015, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VRTX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.679474", "ticker_sentiment_score": "0.168002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AWON", "relevance_score": "0.157483", "ticker_sentiment_score": "0.179347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ARCT", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Group Shows Market Leadership With Jump To 82 RS Rating", "url": "https://www.investors.com/ibd-data-stories/replimune-group-shows-market-leadership-with-jump-to-82-rs-rating/", "time_published": "20230706T070000", "authors": ["Investor's Business Daily", "INVESTOR'S BUSINESS DAILY"], "summary": "When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Replimune Group ( REPL ) , which had its Relative Strength ( RS ) Rating upgraded from 79 to 82 Thursday.", "banner_image": "https://www.investors.com/wp-content/uploads/2016/06/ibd.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.341349, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ARCT", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRTX", "relevance_score": "0.306963", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.570165", "ticker_sentiment_score": "0.528609", "ticker_sentiment_label": "Bullish"}]}, {"title": "Market Rally Broadens Out, Apple Unveils Vision Pro Goggles", "url": "https://www.investors.com/news/stock-market-rally-broadens-out-apple-unveils-vision-pro-sec-sues-binance-coinbase/", "time_published": "20230609T103900", "authors": ["IBD STAFF", "Investor's Business Daily"], "summary": "The stock market rally showed signs of broadening out. The Nasdaq and S&P 500 were little changed, holding near 2023 highs. But the small-cap Russell 2000 and S&P MidCap 400 jumped to three-month highs, while advancers soundly beat decliners.", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-Apple-VisionProGoggles-01-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.972756"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.999998"}], "overall_sentiment_score": 0.049069, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "YEXT", "relevance_score": "0.034185", "ticker_sentiment_score": "0.267189", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.136113", "ticker_sentiment_score": "0.088525", "ticker_sentiment_label": "Neutral"}, {"ticker": "F", "relevance_score": "0.068306", "ticker_sentiment_score": "0.162662", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GM", "relevance_score": "0.068306", "ticker_sentiment_score": "0.162662", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RCUS", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.126932", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.126932", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWON", "relevance_score": "0.034185", "ticker_sentiment_score": "0.267189", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DAWN", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.126932", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.136113", "ticker_sentiment_score": "0.207584", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.202932", "ticker_sentiment_score": "-0.026424", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIEN", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.070421", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVCR", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.15773", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TSLA", "relevance_score": "0.136113", "ticker_sentiment_score": "0.214597", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIO", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.001246", "ticker_sentiment_label": "Neutral"}, {"ticker": "THO", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.113118", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASO", "relevance_score": "0.068306", "ticker_sentiment_score": "-0.094829", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCU", "relevance_score": "0.068306", "ticker_sentiment_score": "0.274867", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GME", "relevance_score": "0.136113", "ticker_sentiment_score": "-0.136419", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLLI", "relevance_score": "0.068306", "ticker_sentiment_score": "0.216568", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.034185", "ticker_sentiment_score": "-0.025381", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress  ( ATC )  Meeting", "url": "https://www.globenewswire.com/news-release/2023/06/06/2683004/0/en/Replimune-Presents-Initial-RP1-Data-from-the-ARTACUS-Clinical-Trial-at-the-2023-American-Transplant-Congress-ATC-Meeting.html", "time_published": "20230606T140000", "authors": ["Replimune Group Inc"], "summary": "Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% ( all complete responses ) in evaluable patients, with all responses ongoing to date Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% ( all complete ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.065265, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.158259", "ticker_sentiment_score": "0.057349", "ticker_sentiment_label": "Neutral"}]}, {"title": "Director at Replimune Group Acquires Company Stock Options Worth 50,400 Shares - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/news/23/06/32717741/director-at-replimune-group-acquires-company-stock-options-worth-50-400-shares", "time_published": "20230605T150028", "authors": ["Benzinga Insights"], "summary": "Veleka PeeplesDyer, Director at Replimune Group REPL, reported a large acquisition of company stock options on June 5, according to a new SEC filing. What Happened: A Form 4 filing from the U.S.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.986714"}], "overall_sentiment_score": 0.214511, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.551295", "ticker_sentiment_score": "0.56363", "ticker_sentiment_label": "Bullish"}]}, {"title": "ASCO News Comes Fast And Furious: ImmunoGen, Day One Surge", "url": "https://www.investors.com/news/technology/imgn-stock-why-this-perfectly-rated-biotech-just-soared-again/", "time_published": "20230605T144900", "authors": ["Investor's Business Daily", "ALLISON GATLIN"], "summary": "IMGN Stock: Why This Perfectly Rated Biotech Just Soared, Again Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/IT03_ImmunoGen_060523news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999956"}], "overall_sentiment_score": 0.087458, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "RCUS", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.339046", "ticker_sentiment_score": "0.310261", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GILD", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.065717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONBI", "relevance_score": "0.0699", "ticker_sentiment_score": "0.0562", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.0699", "ticker_sentiment_score": "-0.055632", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology  ( ASCO )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2023/06/03/2681534/0/en/Replimune-Presents-RP1-Data-from-the-IGNYTE-anti-PD1-Failed-Melanoma-Cohort-and-RP2-Data-in-Uveal-Melanoma-at-the-2023-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html", "time_published": "20230603T181500", "authors": ["Replimune Group Inc"], "summary": "Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile. no progression in responding patients since the data snapshot presented in December ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.004808, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.073098", "ticker_sentiment_score": "0.015384", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.054857", "ticker_sentiment_score": "-0.003", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is a Surprise Coming for Replimune  ( REPL )  This Earnings Season?", "url": "https://www.zacks.com/stock/news/2096342/is-a-surprise-coming-for-replimune-repl-this-earnings-season", "time_published": "20230517T140200", "authors": ["Zacks Investment Research"], "summary": "Replimune (REPL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bc/379.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996675"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.43516, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.917585", "ticker_sentiment_score": "0.679013", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Cara Therapeutics  ( NASDAQ:CARA ) , bluebird bio  ( NASDAQ:BLUE ) ", "url": "https://www.benzinga.com/news/23/04/31787034/top-5-health-care-stocks-which-could-rescue-your-portfolio-this-month", "time_published": "20230413T125952", "authors": ["Lisa Levin"], "summary": "The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/13/image27.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.495866"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.129804, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.355588", "ticker_sentiment_score": "0.013035", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARA", "relevance_score": "0.355588", "ticker_sentiment_score": "0.234112", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BLUE", "relevance_score": "0.270773", "ticker_sentiment_score": "-0.219788", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FULC", "relevance_score": "0.270773", "ticker_sentiment_score": "-0.012866", "ticker_sentiment_label": "Neutral"}, {"ticker": "TKNO", "relevance_score": "0.270773", "ticker_sentiment_score": "0.146937", "ticker_sentiment_label": "Neutral"}]}, {"title": "Century Therapeutics Announces Leadership Changes", "url": "https://www.globenewswire.com/news-release/2023/04/12/2645337/0/en/Century-Therapeutics-Announces-Leadership-Changes.html", "time_published": "20230412T123000", "authors": ["Century Therapeutics", "Inc."], "summary": "- Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors. Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/0c4efad5-3786-4f61-b572-f2b723ecedaa", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.495866"}], "overall_sentiment_score": 0.157875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FOLD", "relevance_score": "0.025166", "ticker_sentiment_score": "-0.003617", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.025166", "ticker_sentiment_score": "-0.069345", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.025166", "ticker_sentiment_score": "-0.003617", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPSC", "relevance_score": "0.125329", "ticker_sentiment_score": "0.139036", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARM", "relevance_score": "0.025166", "ticker_sentiment_score": "-0.069345", "ticker_sentiment_label": "Neutral"}]}, {"title": "Down -22% in 4 Weeks, Here's Why Replimune Group, Inc.  ( REPL )  Looks Ripe for a Turnaround", "url": "https://www.zacks.com/stock/news/2073006/down--22-in-4-weeks-heres-why-replimune-group-inc-repl-looks-ripe-for-a-turnaround", "time_published": "20230331T133506", "authors": ["Zacks Investment Research"], "summary": "The heavy selling pressure might have exhausted for Replimune Group, Inc. (REPL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default57.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.196961, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.482078", "ticker_sentiment_score": "0.263095", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors", "url": "https://www.globenewswire.com/news-release/2023/03/09/2624088/0/en/LAVA-Therapeutics-Announces-Appointment-of-Christy-J-Oliger-to-its-Board-of-Directors.html", "time_published": "20230309T130500", "authors": ["Lava Therapeutics N.V."], "summary": "UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ) , a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers, today announced the appointment ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/4759b844-227f-4632-b22d-4fe63fad55b4?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.155654, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.075635", "ticker_sentiment_score": "-0.06952", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.075635", "ticker_sentiment_score": "0.06787", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.075635", "ticker_sentiment_score": "0.06787", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.295867", "ticker_sentiment_score": "0.011025", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.075635", "ticker_sentiment_score": "0.06787", "ticker_sentiment_label": "Neutral"}]}, {"title": "LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors - LAVA Therapeutics  ( NASDAQ:LVTX ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31275266/lava-therapeutics-announces-appointment-of-christy-j-oliger-to-its-board-of-directors", "time_published": "20230309T130500", "authors": ["Globe Newswire"], "summary": "UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. LVTX, a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody\u2122 platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.146081, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.072876", "ticker_sentiment_score": "-0.064019", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPTI", "relevance_score": "0.072876", "ticker_sentiment_score": "0.067623", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.072876", "ticker_sentiment_score": "0.067623", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.216215", "ticker_sentiment_score": "0.119314", "ticker_sentiment_label": "Neutral"}, {"ticker": "RETA", "relevance_score": "0.072876", "ticker_sentiment_score": "0.067623", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at Two Upcoming Investor Conferences", "url": "https://www.globenewswire.com/news-release/2023/03/08/2622957/0/en/Replimune-to-Present-at-Two-Upcoming-Investor-Conferences.html", "time_published": "20230308T130000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., March 08, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ: REPL ) , a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.00494, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.640349", "ticker_sentiment_score": "-0.007513", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at Two Upcoming Investor Conferences - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/23/03/g31255553/replimune-to-present-at-two-upcoming-investor-conferences", "time_published": "20230308T130000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., March 08, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": -0.004874, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "L", "relevance_score": "0.140076", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.622414", "ticker_sentiment_score": "-0.007397", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.140076", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Group, Inc.  ( REPL )  Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "url": "https://www.zacks.com/stock/news/2058740/replimune-group-inc-repl-loses--1458-in-4-weeks-heres-why-a-trend-reversal-may-be-around-the-corner", "time_published": "20230224T143506", "authors": ["Zacks Investment Research"], "summary": "Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default310.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.996023"}], "overall_sentiment_score": 0.138327, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.489394", "ticker_sentiment_score": "0.144149", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Group, Inc.  ( REPL )  is on the Move, Here's Why the Trend Could be Sustainable", "url": "https://www.zacks.com/stock/news/2052216/replimune-group-inc-repl-is-on-the-move-heres-why-the-trend-could-be-sustainable", "time_published": "20230209T135007", "authors": ["Zacks Investment Research"], "summary": "Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default150.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.395736, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.420316", "ticker_sentiment_score": "0.434243", "ticker_sentiment_label": "Bullish"}]}, {"title": "Wall Street Analysts Think Replimune Group, Inc.  ( REPL )  Could Surge 87.88%: Read This Before Placing a Bet", "url": "https://www.zacks.com/stock/news/2036271/wall-street-analysts-think-replimune-group-inc-repl-could-surge-8788-read-this-before-placing-a-bet", "time_published": "20230106T145505", "authors": ["Zacks Investment Research"], "summary": "The consensus price target hints at an 87.9% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default330.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}], "overall_sentiment_score": 0.20657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.282234", "ticker_sentiment_score": "0.301935", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Recent Price Trend in Replimune Group, Inc.  ( REPL )  is Your Friend, Here's Why", "url": "https://www.zacks.com/stock/news/2036158/recent-price-trend-in-replimune-group-inc-repl-is-your-friend-heres-why", "time_published": "20230106T135005", "authors": ["Zacks Investment Research"], "summary": "Replimune Group, Inc. (REPL) made it through our \"Recent Price Strength\" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default108.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99793"}], "overall_sentiment_score": 0.3924, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.421485", "ticker_sentiment_score": "0.434968", "ticker_sentiment_label": "Bullish"}]}, {"title": "Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/23/01/g30272241/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4", "time_published": "20230104T130500", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies ( TDOIs ) , today announced the grant of inducement equity awards to Chris Sarchi, the ...", "banner_image": "", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.997405"}], "overall_sentiment_score": 0.214741, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.372912", "ticker_sentiment_score": "0.056815", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.globenewswire.com/news-release/2023/01/04/2582888/0/en/Replimune-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html", "time_published": "20230104T130500", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Jan. 04, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies ( TDOIs ) , today announced the grant of inducement equity awards to Chris ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.23183, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.301933", "ticker_sentiment_score": "0.048733", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/23/01/g30255637/replimune-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference", "time_published": "20230103T130000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Jan. 03, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.026798, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.639616", "ticker_sentiment_score": "-0.007469", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference", "url": "https://www.globenewswire.com/news-release/2023/01/03/2582095/0/en/Replimune-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html", "time_published": "20230103T130000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Jan. 03, 2023 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.031843, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.579393", "ticker_sentiment_score": "-0.007114", "ticker_sentiment_label": "Neutral"}]}, {"title": "Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors", "url": "https://www.benzinga.com/pressreleases/22/12/g30073538/umoja-biopharma-appoints-dieter-weinand-as-the-chair-of-its-board-of-directors", "time_published": "20221214T123000", "authors": ["Globe Newswire"], "summary": "SEATTLE, Dec. 14, 2022 ( GLOBE NEWSWIRE ) -- Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced today the appointment of Dieter Weinand to its Board ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.180808, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.11123", "ticker_sentiment_score": "0.052594", "ticker_sentiment_label": "Neutral"}, {"ticker": "REUN", "relevance_score": "0.11123", "ticker_sentiment_score": "0.052594", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.055751", "ticker_sentiment_score": "0.047895", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.055751", "ticker_sentiment_score": "0.047895", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.055751", "ticker_sentiment_score": "0.047895", "ticker_sentiment_label": "Neutral"}]}, {"title": "Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/22/12/30046066/analyst-beefs-up-replimune-price-target-as-recent-data-validates-treatment-platform", "time_published": "20221212T193659", "authors": ["Vandana Singh"], "summary": "Last Thursday, Replimune Group Inc REPL announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. The overall response rate ( ORR ) was 36%, and the complete response ( CR ) rate was 20% compared to the 12.5% shown in ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/12/logo_light__3959434ad89734e0e649ecfca0aee813.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.031432, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.56217", "ticker_sentiment_score": "-0.08847", "ticker_sentiment_label": "Neutral"}]}, {"title": "PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday - Acadia Healthcare Co  ( NASDAQ:ACHC ) , Boeing  ( NYSE:BA ) ", "url": "https://www.benzinga.com/news/22/12/30040797/paypal-to-rally-around-47-here-are-10-other-price-target-changes-for-monday", "time_published": "20221212T133932", "authors": ["Lisa Levin"], "summary": "Barclays raised PayPal Holdings, Inc. PYPL price target from $100 to $108. . Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. PayPal shares fell 0.9% to close at $73.57 on Friday. Citigroup boosted The Cooper Companies, Inc. COO price target from $348 to $368.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/12/image-paypal.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.110206, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.188881", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COO", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.031089", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHC", "relevance_score": "0.272788", "ticker_sentiment_score": "0.304906", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BGNE", "relevance_score": "0.272788", "ticker_sentiment_score": "0.277959", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.022811", "ticker_sentiment_label": "Neutral"}, {"ticker": "JPM", "relevance_score": "0.358152", "ticker_sentiment_score": "0.086631", "ticker_sentiment_label": "Neutral"}, {"ticker": "MU", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.113595", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.272788", "ticker_sentiment_score": "0.289282", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CCORF", "relevance_score": "0.092569", "ticker_sentiment_score": "0.14835", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMS", "relevance_score": "0.272788", "ticker_sentiment_score": "-0.174137", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BCS", "relevance_score": "0.183895", "ticker_sentiment_score": "-0.139468", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.272788", "ticker_sentiment_score": "0.140461", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHX", "relevance_score": "0.272788", "ticker_sentiment_score": "0.006161", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.272788", "ticker_sentiment_score": "0.130304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Pricing of Public Offering - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/22/12/g30017013/replimune-announces-pricing-of-public-offering", "time_published": "20221209T020434", "authors": ["Globe Newswire"], "summary": "BOSTON, Dec. 08, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a ...", "banner_image": "", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.890401"}, {"topic": "Financial Markets", "relevance_score": "0.999894"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.113614, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.059488", "ticker_sentiment_score": "0.042992", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.498188", "ticker_sentiment_score": "0.261094", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.059488", "ticker_sentiment_score": "0.042992", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Pricing of Public Offering", "url": "https://www.globenewswire.com/news-release/2022/12/09/2570761/0/en/Replimune-Announces-Pricing-of-Public-Offering.html", "time_published": "20221209T020400", "authors": ["Replimune Group Inc"], "summary": "BOSTON, Dec. 08, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( Nasdaq: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.972193"}, {"topic": "Financial Markets", "relevance_score": "0.999939"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.05718, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.040484", "ticker_sentiment_score": "0.043426", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.388276", "ticker_sentiment_score": "0.124516", "ticker_sentiment_label": "Neutral"}, {"ticker": "STT", "relevance_score": "0.040484", "ticker_sentiment_score": "0.043426", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Proposed Public Offering - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/22/12/g29998497/replimune-announces-proposed-public-offering", "time_published": "20221207T210404", "authors": ["Globe Newswire"], "summary": "BOSTON, Dec. 07, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and ...", "banner_image": "", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "0.99246"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.107077, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BR", "relevance_score": "0.073098", "ticker_sentiment_score": "0.068456", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.537018", "ticker_sentiment_score": "0.275693", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STT", "relevance_score": "0.073098", "ticker_sentiment_score": "0.068456", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Replimune  ( REPL )  Shares Are Trading Higher Today - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ", "url": "https://www.benzinga.com/general/biotech/22/12/29991461/replimune-shares-surge-after-early-data-from-pretreated-melanoma-patients", "time_published": "20221207T150511", "authors": ["Vandana Singh"], "summary": "Replimune Group Inc REPL announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 ( vusolimogene oderparepvec ) combined with Bristol-Myers Squibb Co's BMY Opdivo ( nivolumab ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/12/07/repl_logo_light__3959434ad89734e0e649ecfca0aee813.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.18661, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.679474", "ticker_sentiment_score": "-0.078698", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.308891", "ticker_sentiment_score": "-0.187502", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/22/12/g29988444/replimune-announces-positive-initial-data-from-the-anti-pd1-failed-melanoma-cohort-of-the-ignyte-c", "time_published": "20221207T120000", "authors": ["Globe Newswire"], "summary": "RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": -0.012029, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.120087", "ticker_sentiment_score": "0.03288", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.03443", "ticker_sentiment_score": "-0.076535", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update", "url": "https://www.globenewswire.com/news-release/2022/12/07/2569129/0/en/Replimune-Announces-Positive-Initial-Data-from-the-Anti-PD1-Failed-Melanoma-Cohort-of-the-IGNYTE-Clinical-Trial-an-RP2-3-Program-Update.html", "time_published": "20221207T120000", "authors": ["Replimune Group Inc"], "summary": "RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": -0.019253, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.101012", "ticker_sentiment_score": "0.025242", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.033751", "ticker_sentiment_score": "-0.019351", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma", "url": "https://www.globenewswire.com/news-release/2022/12/07/2569082/0/en/Replimune-Enters-into-Clinical-Collaboration-Agreement-with-Roche-for-the-Development-of-RP3-In-Colorectal-Cancer-and-Hepatocellular-Carcinoma.html", "time_published": "20221207T113000", "authors": ["Replimune Group Inc"], "summary": "RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer ( CRC ) and for the first- and second-line treatment of hepatocellular carcinoma ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.091225, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.232439", "ticker_sentiment_score": "0.085983", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.039289", "ticker_sentiment_score": "0.130186", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts - Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/general/biotech/22/10/29272033/replimune-gets-33-price-target-bump-ahead-of-upcoming-readouts-analyst-lists-the-catalysts", "time_published": "20221014T175220", "authors": ["Vandana Singh"], "summary": "BMO Capital Markets raised the price target on Replimune Group Inc REPL to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous squamous cell carcinoma ( CSCC ) .", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/14/aapharma_11.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.372608, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMGN", "relevance_score": "0.345674", "ticker_sentiment_score": "0.556144", "ticker_sentiment_label": "Bullish"}, {"ticker": "HTGC", "relevance_score": "0.345674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.629492", "ticker_sentiment_score": "0.459674", "ticker_sentiment_label": "Bullish"}]}, {"title": "Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - Hercules Capital  ( NYSE:HTGC ) , Replimune Group  ( NASDAQ:REPL ) ", "url": "https://www.benzinga.com/pressreleases/22/10/g29182791/replimune-secures-200-million-in-non-dilutive-debt-financing-from-hercules-capital-inc", "time_published": "20221007T120000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., Oct. 07, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. REPL, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan facility from ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.194182, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTGC", "relevance_score": "0.190167", "ticker_sentiment_score": "0.119843", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.425541", "ticker_sentiment_score": "0.195725", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.", "url": "https://www.globenewswire.com/news-release/2022/10/07/2530240/0/en/Replimune-Secures-200-Million-in-Non-Dilutive-Debt-Financing-from-Hercules-Capital-Inc.html", "time_published": "20221007T120000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., Oct. 07, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that it has obtained a $200 million non-dilutive term loan ...", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}], "overall_sentiment_score": 0.159208, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HTGC", "relevance_score": "0.087503", "ticker_sentiment_score": "0.083655", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.258351", "ticker_sentiment_score": "0.137548", "ticker_sentiment_label": "Neutral"}]}, {"title": "Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday - Axcella Health  ( NASDAQ:AXLA ) , Intercept Pharmaceuticals  ( NASDAQ:ICPT ) ", "url": "https://www.benzinga.com/news/22/10/29115193/wells-fargo-to-surge-around-20-here-are-5-other-price-target-changes-for-monday", "time_published": "20221003T111602", "authors": ["Lisa Levin"], "summary": "Goldman Sachs raised Wells Fargo & Company WFC price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68 in pre-market trading. Baird cut the price target on Intercept Pharmaceuticals, Inc. ICPT from $52 to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/03/image-wells_fargo.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.017135, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.470894", "ticker_sentiment_score": "0.250902", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AXLA", "relevance_score": "0.470894", "ticker_sentiment_score": "0.126571", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.325208", "ticker_sentiment_score": "0.348646", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ICPT", "relevance_score": "0.470894", "ticker_sentiment_score": "0.006353", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.470894", "ticker_sentiment_score": "0.442305", "ticker_sentiment_label": "Bullish"}, {"ticker": "LTHM", "relevance_score": "0.470894", "ticker_sentiment_score": "-0.387221", "ticker_sentiment_label": "Bearish"}]}, {"title": "Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks", "url": "https://www.fool.com/investing/2022/08/24/billionaires-are-scooping-up-these-2-beaten-down-b/", "time_published": "20220824T115800", "authors": ["George Budwell"], "summary": "This billionaire-guided hedge fund went bargain-shopping in the second quarter.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F697403%2Fno-crisis_man-under-umbrella.jpg&w=700&op=resize", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.995077"}], "overall_sentiment_score": 0.055925, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CERS", "relevance_score": "0.294682", "ticker_sentiment_score": "0.190718", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.294682", "ticker_sentiment_score": "-0.079799", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.050254", "ticker_sentiment_score": "0.00702", "ticker_sentiment_label": "Neutral"}]}, {"title": "Immuno-oncology Consolidating its Presence in Most Major Types of Cancer | Globaldata Plc", "url": "https://www.globenewswire.com/news-release/2022/07/05/2474145/0/en/Immuno-oncology-Consolidating-its-Presence-in-Most-Major-Types-of-Cancer-Globaldata-Plc.html", "time_published": "20220705T140000", "authors": ["GlobalData UK Ltd"], "summary": "There are currently 69 marketed immuno-oncology ( IO ) agents in the 8MM There are currently 69 marketed immuno-oncology ( IO ) agents in the ...", "banner_image": "https://ml-eu.globenewswire.com/Resource/Download/57162fb0-6e92-435b-9aa5-0ab0515f59c7?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.043796, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "LEGN", "relevance_score": "0.030755", "ticker_sentiment_score": "0.003514", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNCE", "relevance_score": "0.603685", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMAB", "relevance_score": "0.030755", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NLTX", "relevance_score": "0.122565", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.030755", "ticker_sentiment_score": "0.003514", "ticker_sentiment_label": "Neutral"}, {"ticker": "III", "relevance_score": "0.061465", "ticker_sentiment_score": "0.058141", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCUS", "relevance_score": "0.328514", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.182944", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.030755", "ticker_sentiment_score": "0.022754", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONCR", "relevance_score": "0.061465", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.122565", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "VBIV", "relevance_score": "0.581867", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.030755", "ticker_sentiment_score": "0.003514", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRT", "relevance_score": "0.719659", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.719659", "ticker_sentiment_score": "0.00256", "ticker_sentiment_label": "Neutral"}, {"ticker": "GILD", "relevance_score": "0.030755", "ticker_sentiment_score": "0.003514", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.030755", "ticker_sentiment_score": "0.003514", "ticker_sentiment_label": "Neutral"}]}, {"title": "Revolution Medicines Advances First RAS ( ON )  Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236", "url": "https://www.globenewswire.com/news-release/2022/06/28/2470203/0/en/Revolution-Medicines-Advances-First-RAS-ON-Inhibitor-into-Clinic-Dosing-First-Patient-in-Phase-1-1b-Trial-of-RMC-6236.html", "time_published": "20220628T110000", "authors": ["Inc.", "Revolution Medicines"], "summary": "First-in-class, oral, RAS ( ON ) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations ...", "banner_image": "https://ml.globenewswire.com/Resource/Download/11b9b98e-0ef7-4a2e-8bba-71e7bde12cad?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.034539, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.033319", "ticker_sentiment_score": "0.026284", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVMD", "relevance_score": "0.412887", "ticker_sentiment_score": "0.036366", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Announces the Departure of Jason Rhodes from its Board of Directors", "url": "https://www.benzinga.com/pressreleases/22/06/g27540623/replimune-announces-the-departure-of-jason-rhodes-from-its-board-of-directors", "time_published": "20220603T120000", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., June 03, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ:REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from th", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.184853, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.339245", "ticker_sentiment_score": "0.344331", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune Announces the Departure of Jason Rhodes from its Board of Directors", "url": "https://www.globenewswire.com/news-release/2022/06/03/2455952/0/en/Replimune-Announces-the-Departure-of-Jason-Rhodes-from-its-Board-of-Directors.html", "time_published": "20220603T120000", "authors": ["Replimune Group Inc"], "summary": "WOBURN, Mass., June 03, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ: REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Jason Rhodes, partner at Atlas Venture, has resigned from t", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.187931, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.307603", "ticker_sentiment_score": "0.328026", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting", "url": "https://www.benzinga.com/pressreleases/22/05/g27432191/replimune-to-present-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting", "time_published": "20220526T211500", "authors": ["Globe Newswire"], "summary": "WOBURN, Mass., May 26, 2022 ( GLOBE NEWSWIRE ) -- Replimune Group, Inc. ( NASDAQ:REPL ) , a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinic", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.001917, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.152653", "ticker_sentiment_score": "0.007808", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.061378", "ticker_sentiment_score": "0.009621", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.030712", "ticker_sentiment_score": "0.002078", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune To Present at the 2022 American Society of Clinical Oncology  ( ASCO )  Annual Meeting", "url": "https://www.globenewswire.com/news-release/2022/05/26/2451683/0/en/Replimune-To-Present-at-the-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html", "time_published": "20220526T211500", "authors": ["Replimune Group Inc"], "summary": "Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase 1/2 study of RP1 combined with Opdivo\u00ae ( nivolumab ) , and trial-in-progress updates across the RP1, RP2 and RP3 programs Presentations include recently updated results from the skin cancer cohort", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.007699, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.137809", "ticker_sentiment_score": "0.007694", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.069164", "ticker_sentiment_score": "0.010004", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.034615", "ticker_sentiment_score": "0.003278", "ticker_sentiment_label": "Neutral"}]}, {"title": "PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst", "url": "https://www.benzinga.com/analyst-ratings/analyst-color/22/05/27402845/premarket-prep-4-biotech-picks", "time_published": "20220525T184032", "authors": ["Joel Elconin"], "summary": "Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech ( NYSE: XBI ) peaked in February 2021 and is now 60% lower than its all-time high price ( $174.79 vs. $66.50 ) . While many issues have lost even more of their", "banner_image": "https://lh6.googleusercontent.com/kjrjAsb9a-PgN9xg2v1SPQ_NnZg47ko5WFOSdTNyg55LqCHPtuDGqgoc4JkVM5F9oCUq546czfPOCAUSRC0hK3WSageYKv967sdfsW5-MAxkwtzD0eZ60BHM7uu18cyDo5KxDC1g3dLo4RiGmg", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": -0.0145, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TNGX", "relevance_score": "0.168726", "ticker_sentiment_score": "0.012065", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.168726", "ticker_sentiment_score": "0.006426", "ticker_sentiment_label": "Neutral"}, {"ticker": "KURA", "relevance_score": "0.168726", "ticker_sentiment_score": "0.03087", "ticker_sentiment_label": "Neutral"}]}, {"title": "Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results", "url": "https://www.globenewswire.com/news-release/2022/05/09/2438365/0/en/Beam-Therapeutics-Announces-Pipeline-and-Business-Highlights-and-Reports-First-Quarter-2022-Financial-Results.html", "time_published": "20220509T103000", "authors": ["Beam Therapeutics"], "summary": "BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022", "banner_image": "https://ml.globenewswire.com/Resource/Download/03af3276-c254-436a-b40d-2ad9a1025f95?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.114203, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.377455", "ticker_sentiment_score": "0.19347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "REPL", "relevance_score": "0.019636", "ticker_sentiment_score": "0.077164", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stocks That Hit 52-Week Lows On Friday", "url": "https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article", "time_published": "20220506T160650", "authors": ["Benzinga Insights"], "summary": "On Friday, 1043 companies hit new 52-week lows.\nInteresting Points From Today's 52-Week Lows:\nThe largest company by market cap to set a new 52-week low was Amazon.com  ( NASDAQ:AMZN ) .\nThe smallest company by market cap to set a new 52-week low was Digital Brands Group  ( NASDAQ:DBGI ) .\nDigital B", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/movers_image_8140.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Blockchain", "relevance_score": "0.451494"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": -0.018654, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AVIR", "relevance_score": "0.005467", "ticker_sentiment_score": "8e-06", "ticker_sentiment_label": "Neutral"}, {"ticker": "PATH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.014739", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007715", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIRI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001369", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOFO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002362", "ticker_sentiment_label": "Neutral"}, {"ticker": "SHYF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001586", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015322", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007408", "ticker_sentiment_label": "Neutral"}, {"ticker": "XXII", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009055", "ticker_sentiment_label": "Neutral"}, {"ticker": "WYNN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004464", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRSX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004759", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.01506", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGEN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011593", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLMA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001593", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCOR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006114", "ticker_sentiment_label": "Neutral"}, {"ticker": "BILL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.474612", "ticker_sentiment_label": "Bearish"}, {"ticker": "QTWO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012224", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOLD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.024001", "ticker_sentiment_label": "Neutral"}, {"ticker": "AB", "relevance_score": "0.002733", "ticker_sentiment_score": "0.000797", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTCM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011692", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARBK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001746", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYZN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001565", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMKR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001468", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007395", "ticker_sentiment_label": "Neutral"}, {"ticker": "HESG", "relevance_score": "0.002733", "ticker_sentiment_score": "0.002022", "ticker_sentiment_label": "Neutral"}, {"ticker": "WINT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00383", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSNC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001562", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAMP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015383", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARAY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.129948", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRIX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006773", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTBT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004773", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001338", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCEL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.034278", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCAB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000513", "ticker_sentiment_label": "Neutral"}, {"ticker": "UIS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.040341", "ticker_sentiment_label": "Neutral"}, {"ticker": "BB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012428", "ticker_sentiment_label": "Neutral"}, {"ticker": "EJH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001005", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIQT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001112", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016909", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBLA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.036375", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.023456", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000242", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTOO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006596", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXON", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009028", "ticker_sentiment_label": "Neutral"}, {"ticker": "BL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00231", "ticker_sentiment_label": "Neutral"}, {"ticker": "FATE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008036", "ticker_sentiment_label": "Neutral"}, {"ticker": "LGND", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00032", "ticker_sentiment_label": "Neutral"}, {"ticker": "S", "relevance_score": "0.002733", "ticker_sentiment_score": "-0.01088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001986", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDAK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002803", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABCM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.024212", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAPT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.014222", "ticker_sentiment_label": "Neutral"}, {"ticker": "U", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003095", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACEL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001119", "ticker_sentiment_label": "Neutral"}, {"ticker": "W", "relevance_score": "0.005467", "ticker_sentiment_score": "0.052688", "ticker_sentiment_label": "Neutral"}, {"ticker": "Z", "relevance_score": "0.0082", "ticker_sentiment_score": "-0.007807", "ticker_sentiment_label": "Neutral"}, {"ticker": "CECE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005194", "ticker_sentiment_label": "Neutral"}, {"ticker": "LYG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013762", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005592", "ticker_sentiment_label": "Neutral"}, {"ticker": "SFT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005844", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBKR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009328", "ticker_sentiment_label": "Neutral"}, {"ticker": "USIO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012453", "ticker_sentiment_label": "Neutral"}, {"ticker": "VISL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004647", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVLR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004948", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.024503", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMAB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002076", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYMD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000807", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFSL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00089", "ticker_sentiment_label": "Neutral"}, {"ticker": "YSG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005297", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEXAF", "relevance_score": "0.002733", "ticker_sentiment_score": "-0.004931", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRDN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001828", "ticker_sentiment_label": "Neutral"}, {"ticker": "DIS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013388", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.23749", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BKSY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002256", "ticker_sentiment_label": "Neutral"}, {"ticker": "REE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003607", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRKA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011872", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIRT", "relevance_score": "0.005467", "ticker_sentiment_score": "-8.6e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFFN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00252", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.013198", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDUS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020137", "ticker_sentiment_label": "Neutral"}, {"ticker": "TIL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020564", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIRS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005341", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZTA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01126", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLRO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00157", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004358", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALXO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005188", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVET", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012266", "ticker_sentiment_label": "Neutral"}, {"ticker": "EYEN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001055", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLBZ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.311797", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AMZN", "relevance_score": "0.010933", "ticker_sentiment_score": "0.03713", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLPX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000599", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009637", "ticker_sentiment_label": "Neutral"}, {"ticker": "VMW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003057", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITRM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017429", "ticker_sentiment_label": "Neutral"}, {"ticker": "RARE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.014996", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.029089", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001112", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003114", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.0008", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRTS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.016288", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISPO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.014144", "ticker_sentiment_label": "Neutral"}, {"ticker": "TALK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008835", "ticker_sentiment_label": "Neutral"}, {"ticker": "TBNK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.022839", "ticker_sentiment_label": "Neutral"}, {"ticker": "INFN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002688", "ticker_sentiment_label": "Neutral"}, {"ticker": "WISH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01261", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCTI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000697", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005777", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABEO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017979", "ticker_sentiment_label": "Neutral"}, {"ticker": "LITM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.031719", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTCO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001659", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADIL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00094", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAPP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.080114", "ticker_sentiment_label": "Neutral"}, {"ticker": "EA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012633", "ticker_sentiment_label": "Neutral"}, {"ticker": "EH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000665", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004234", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEMD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001816", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYTU", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003547", "ticker_sentiment_label": "Neutral"}, {"ticker": "PBYI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000255", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.236976", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MTEM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010779", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDWR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003915", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01322", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.04504", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLDB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003646", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRMB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003051", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYOV", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005439", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.034088", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPLK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015781", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEJO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007337", "ticker_sentiment_label": "Neutral"}, {"ticker": "BHC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.018307", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVGW", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013234", "ticker_sentiment_label": "Neutral"}, {"ticker": "QRVO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00024", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISPC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.035619", "ticker_sentiment_label": "Neutral"}, {"ticker": "NLSP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000154", "ticker_sentiment_label": "Neutral"}, {"ticker": "STTK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006624", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015607", "ticker_sentiment_label": "Neutral"}, {"ticker": "SIX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000819", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001435", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGEN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001422", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPRO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.013934", "ticker_sentiment_label": "Neutral"}, {"ticker": "CBAY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.268097", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ENS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012076", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.013666", "ticker_sentiment_score": "0.006812", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNGX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.009472", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFLY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.07076", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACIU", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001962", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.273034", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SLGC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016342", "ticker_sentiment_label": "Neutral"}, {"ticker": "HARP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006369", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRWG", "relevance_score": "0.005467", "ticker_sentiment_score": "-6.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017042", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRTG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002798", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUNA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005366", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMTK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004709", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.058432", "ticker_sentiment_label": "Neutral"}, {"ticker": "GH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.031278", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRBP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003189", "ticker_sentiment_label": "Neutral"}, {"ticker": "JBLU", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.027782", "ticker_sentiment_label": "Neutral"}, {"ticker": "BITF", "relevance_score": "0.005467", "ticker_sentiment_score": "0.013102", "ticker_sentiment_label": "Neutral"}, {"ticker": "NLTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010952", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSSS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.226453", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AVPT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01004", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSTO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008074", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLZE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.061768", "ticker_sentiment_label": "Neutral"}, {"ticker": "INGN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.040384", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNLX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000491", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELOX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001721", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00805", "ticker_sentiment_label": "Neutral"}, {"ticker": "SSTK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.034103", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXTI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012549", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPNE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007001", "ticker_sentiment_label": "Neutral"}, {"ticker": "LQDT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01047", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004451", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLVS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.199823", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GTH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006255", "ticker_sentiment_label": "Neutral"}, {"ticker": "HD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006344", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRRK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.027141", "ticker_sentiment_label": "Neutral"}, {"ticker": "QNRX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000398", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.022958", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMSWA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006198", "ticker_sentiment_label": "Neutral"}, {"ticker": "FGEN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.044346", "ticker_sentiment_label": "Neutral"}, {"ticker": "KNDI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.014461", "ticker_sentiment_label": "Neutral"}, {"ticker": "XELA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00032", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTEA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.251893", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EGHT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.076938", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006349", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002389", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.409825", "ticker_sentiment_label": "Bearish"}, {"ticker": "SLS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000645", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004714", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZYNE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001534", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLMD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00345", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNDA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001229", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVLT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016298", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008228", "ticker_sentiment_label": "Neutral"}, {"ticker": "MPAA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.048692", "ticker_sentiment_label": "Neutral"}, {"ticker": "AIP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009323", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSV", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005174", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSGM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006195", "ticker_sentiment_label": "Neutral"}, {"ticker": "IR", "relevance_score": "0.005467", "ticker_sentiment_score": "2e-06", "ticker_sentiment_label": "Neutral"}, {"ticker": "IS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.084388", "ticker_sentiment_label": "Neutral"}, {"ticker": "MREO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.094167", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVRO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000887", "ticker_sentiment_label": "Neutral"}, {"ticker": "HRTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.009445", "ticker_sentiment_label": "Neutral"}, {"ticker": "OEG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000875", "ticker_sentiment_label": "Neutral"}, {"ticker": "CGNX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003603", "ticker_sentiment_label": "Neutral"}, {"ticker": "JAMF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.027567", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIMV", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004583", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.0292", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOND", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001993", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATNF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.119529", "ticker_sentiment_label": "Neutral"}, {"ticker": "KERN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.04525", "ticker_sentiment_label": "Neutral"}, {"ticker": "MITK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002805", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.033035", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLXT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007984", "ticker_sentiment_label": "Neutral"}, {"ticker": "DYNT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000961", "ticker_sentiment_label": "Neutral"}, {"ticker": "SONO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012775", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBGI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.025156", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLK", "relevance_score": "0.03279", "ticker_sentiment_score": "-0.036069", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBEV", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006809", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATOS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004931", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000607", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKLB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011983", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003726", "ticker_sentiment_label": "Neutral"}, {"ticker": "IONQ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000361", "ticker_sentiment_label": "Neutral"}, {"ticker": "SZCRF", "relevance_score": "0.002733", "ticker_sentiment_score": "0.006114", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRNT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005723", "ticker_sentiment_label": "Neutral"}, {"ticker": "DPZ", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011699", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015929", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOXF", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002884", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001268", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAFN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000318", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLOB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.043899", "ticker_sentiment_label": "Neutral"}, {"ticker": "PHR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008608", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBCI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007081", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKIL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.02263", "ticker_sentiment_label": "Neutral"}, {"ticker": "INMD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002717", "ticker_sentiment_label": "Neutral"}, {"ticker": "MBIO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.258621", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "COO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00397", "ticker_sentiment_label": "Neutral"}, {"ticker": "OFIX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006809", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002062", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012228", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.02661", "ticker_sentiment_label": "Neutral"}, {"ticker": "INKT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000997", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOPH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011193", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPLD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.013174", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMBA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006793", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006695", "ticker_sentiment_label": "Neutral"}, {"ticker": "WWW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004219", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRDS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006041", "ticker_sentiment_label": "Neutral"}, {"ticker": "IART", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004581", "ticker_sentiment_label": "Neutral"}, {"ticker": "XFOR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005917", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADPT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002869", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBIO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00512", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHRS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003111", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVNA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013203", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007206", "ticker_sentiment_label": "Neutral"}, {"ticker": "LE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003064", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000646", "ticker_sentiment_label": "Neutral"}, {"ticker": "KTRA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000239", "ticker_sentiment_label": "Neutral"}, {"ticker": "TARA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.265921", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "USX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000322", "ticker_sentiment_label": "Neutral"}, {"ticker": "KMDA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.043956", "ticker_sentiment_label": "Neutral"}, {"ticker": "NET", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002616", "ticker_sentiment_label": "Neutral"}, {"ticker": "FUBO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003623", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRDY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.014188", "ticker_sentiment_label": "Neutral"}, {"ticker": "KBNT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.040211", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.027933", "ticker_sentiment_label": "Neutral"}, {"ticker": "NPCE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002119", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004457", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002266", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOGI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007082", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008507", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004771", "ticker_sentiment_label": "Neutral"}, {"ticker": "VVI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000108", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004933", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008819", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOAH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.03789", "ticker_sentiment_label": "Neutral"}, {"ticker": "KPLT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01756", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSII", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000825", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRVN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001977", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTCH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.698832", "ticker_sentiment_label": "Bearish"}, {"ticker": "DTIL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01385", "ticker_sentiment_label": "Neutral"}, {"ticker": "IPSC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012995", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTKB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002907", "ticker_sentiment_label": "Neutral"}, {"ticker": "ME", "relevance_score": "0.002733", "ticker_sentiment_score": "0.001371", "ticker_sentiment_label": "Neutral"}, {"ticker": "AME", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012928", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLNE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006004", "ticker_sentiment_label": "Neutral"}, {"ticker": "UTZ", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002859", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACOR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.030168", "ticker_sentiment_label": "Neutral"}, {"ticker": "ML", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013365", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTLA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000206", "ticker_sentiment_label": "Neutral"}, {"ticker": "EKSO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003713", "ticker_sentiment_label": "Neutral"}, {"ticker": "MQ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015197", "ticker_sentiment_label": "Neutral"}, {"ticker": "KRON", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002744", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003802", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMMT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003118", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEGA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011322", "ticker_sentiment_label": "Neutral"}, {"ticker": "FMTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.088737", "ticker_sentiment_label": "Neutral"}, {"ticker": "LVTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001296", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002271", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMPZF", "relevance_score": "0.002733", "ticker_sentiment_score": "0.011699", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDLX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.032558", "ticker_sentiment_label": "Neutral"}, {"ticker": "DTC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010496", "ticker_sentiment_label": "Neutral"}, {"ticker": "EBAY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016762", "ticker_sentiment_label": "Neutral"}, {"ticker": "NGM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00505", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXLW", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.126406", "ticker_sentiment_label": "Neutral"}, {"ticker": "CENT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004043", "ticker_sentiment_label": "Neutral"}, {"ticker": "REAL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.231438", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ATRC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005503", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003601", "ticker_sentiment_label": "Neutral"}, {"ticker": "NH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002642", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006202", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRUP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016006", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMCX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.322204", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CRM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006243", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERAS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001254", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004234", "ticker_sentiment_label": "Neutral"}, {"ticker": "JRSH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001954", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKLZ", "relevance_score": "0.005467", "ticker_sentiment_score": "-1.3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.057756", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRCH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.314355", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TTC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.014229", "ticker_sentiment_label": "Neutral"}, {"ticker": "VAPO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00678", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTMX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005629", "ticker_sentiment_label": "Neutral"}, {"ticker": "VCTR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.11505", "ticker_sentiment_label": "Neutral"}, {"ticker": "COCP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003534", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRIS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.031284", "ticker_sentiment_label": "Neutral"}, {"ticker": "NU", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.085718", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006355", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKAM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007852", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXPE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001378", "ticker_sentiment_label": "Neutral"}, {"ticker": "LANC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004429", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDNA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.039126", "ticker_sentiment_label": "Neutral"}, {"ticker": "LDI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001517", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020486", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANGI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010664", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMED", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00714", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLSI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002944", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTBP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007612", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABOS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.056186", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDMO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005764", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBLN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.232694", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017063", "ticker_sentiment_label": "Neutral"}, {"ticker": "DSGX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004039", "ticker_sentiment_label": "Neutral"}, {"ticker": "PYPL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005847", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALDX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012919", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVYA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.018945", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAOI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002418", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNUS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.024422", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011084", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIHO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017889", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCPC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005167", "ticker_sentiment_label": "Neutral"}, {"ticker": "VLDR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008599", "ticker_sentiment_label": "Neutral"}, {"ticker": "MVST", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNED", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001835", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAYW", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001919", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMDX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007904", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVXL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000505", "ticker_sentiment_label": "Neutral"}, {"ticker": "APG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.044445", "ticker_sentiment_label": "Neutral"}, {"ticker": "PH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007168", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000657", "ticker_sentiment_label": "Neutral"}, {"ticker": "WTRH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007032", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEV", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009564", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTDR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004855", "ticker_sentiment_label": "Neutral"}, {"ticker": "FXLV", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004686", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBGI", "relevance_score": "0.013666", "ticker_sentiment_score": "0.045786", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLTO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008852", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZUMZ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007579", "ticker_sentiment_label": "Neutral"}, {"ticker": "FEIM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000683", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADVM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003623", "ticker_sentiment_label": "Neutral"}, {"ticker": "XSPA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.101736", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCNC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005012", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCNA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010982", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANIK", "relevance_score": "0.005467", "ticker_sentiment_score": "7.1e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "CUE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.02523", "ticker_sentiment_label": "Neutral"}, {"ticker": "OLO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012228", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRIO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011803", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003633", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOCN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011031", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMSI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.017866", "ticker_sentiment_label": "Neutral"}, {"ticker": "TKLF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001304", "ticker_sentiment_label": "Neutral"}, {"ticker": "CHWY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005449", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORIC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011765", "ticker_sentiment_label": "Neutral"}, {"ticker": "INSG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002028", "ticker_sentiment_label": "Neutral"}, {"ticker": "CODX", "relevance_score": "0.005467", "ticker_sentiment_score": "-3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELYS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009228", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVRO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.176704", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ILMN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.019739", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABSI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.129262", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMBM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.016593", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.022574", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNGO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000153", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSQR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.043663", "ticker_sentiment_label": "Neutral"}, {"ticker": "AEYE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002505", "ticker_sentiment_label": "Neutral"}, {"ticker": "CURO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.182188", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GMVD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002648", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCMI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003056", "ticker_sentiment_label": "Neutral"}, {"ticker": "RNWK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012718", "ticker_sentiment_label": "Neutral"}, {"ticker": "WLDN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000923", "ticker_sentiment_label": "Neutral"}, {"ticker": "IAS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012214", "ticker_sentiment_label": "Neutral"}, {"ticker": "RL", "relevance_score": "0.005467", "ticker_sentiment_score": "3.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMRT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.01715", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUBS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010254", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNEY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.028703", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008803", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTTR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001075", "ticker_sentiment_label": "Neutral"}, {"ticker": "SVC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003672", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRAY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.048687", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006639", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZEPP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002373", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLDP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.028201", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIAN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000207", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00265", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDLB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005483", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRGO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.306708", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PENN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004995", "ticker_sentiment_label": "Neutral"}, {"ticker": "SE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00298", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCRX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001646", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRMD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006674", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEEL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001419", "ticker_sentiment_label": "Neutral"}, {"ticker": "CWT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.021491", "ticker_sentiment_label": "Neutral"}, {"ticker": "TYL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001436", "ticker_sentiment_label": "Neutral"}, {"ticker": "LII", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.10492", "ticker_sentiment_label": "Neutral"}, {"ticker": "MANH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020113", "ticker_sentiment_label": "Neutral"}, {"ticker": "APPN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.050619", "ticker_sentiment_label": "Neutral"}, {"ticker": "CETX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006791", "ticker_sentiment_label": "Neutral"}, {"ticker": "GTES", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010455", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIOT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.0063", "ticker_sentiment_label": "Neutral"}, {"ticker": "TEAM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.181627", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TOUR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007888", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZEK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006728", "ticker_sentiment_label": "Neutral"}, {"ticker": "TU", "relevance_score": "0.002733", "ticker_sentiment_score": "-0.039919", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMWB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.031993", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005647", "ticker_sentiment_label": "Neutral"}, {"ticker": "CROX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.039985", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALIT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.036653", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVRI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.016514", "ticker_sentiment_label": "Neutral"}, {"ticker": "BOLT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.019148", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004549", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002594", "ticker_sentiment_label": "Neutral"}, {"ticker": "UA", "relevance_score": "0.0082", "ticker_sentiment_score": "0.002169", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000687", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLYC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.399338", "ticker_sentiment_label": "Bearish"}, {"ticker": "HBI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000129", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00448", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.02444", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRGI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001127", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDHL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001434", "ticker_sentiment_label": "Neutral"}, {"ticker": "FIVE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002927", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005529", "ticker_sentiment_label": "Neutral"}, {"ticker": "PZZA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.216241", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EWTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00763", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFFP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007568", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006633", "ticker_sentiment_label": "Neutral"}, {"ticker": "PIXY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.082156", "ticker_sentiment_label": "Neutral"}, {"ticker": "YETI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010178", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONCR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000321", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPGN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.021783", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.029358", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015918", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.123083", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOW", "relevance_score": "0.002733", "ticker_sentiment_score": "-0.014079", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARVL", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007326", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAKT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.231255", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CZR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.046173", "ticker_sentiment_label": "Neutral"}, {"ticker": "APRE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.342782", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "IEX", "relevance_score": "0.002733", "ticker_sentiment_score": "0.003273", "ticker_sentiment_label": "Neutral"}, {"ticker": "RCEL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000491", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTCF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000512", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007898", "ticker_sentiment_label": "Neutral"}, {"ticker": "HDB", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003474", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007337", "ticker_sentiment_label": "Neutral"}, {"ticker": "AHCO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020501", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.20525", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RPAY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001644", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGMO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004712", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARWR", "relevance_score": "0.005467", "ticker_sentiment_score": "-8.8e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "AWH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.005839", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTGM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000117", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENDP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007389", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNXP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001608", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOCS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013813", "ticker_sentiment_label": "Neutral"}, {"ticker": "SDGR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002045", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECOM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007048", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMNL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01293", "ticker_sentiment_label": "Neutral"}, {"ticker": "NCTY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.05687", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRLD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008196", "ticker_sentiment_label": "Neutral"}, {"ticker": "MARA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002175", "ticker_sentiment_label": "Neutral"}, {"ticker": "HIPO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011886", "ticker_sentiment_label": "Neutral"}, {"ticker": "WATT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006975", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORMP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017878", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMUX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008648", "ticker_sentiment_label": "Neutral"}, {"ticker": "HLVX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000955", "ticker_sentiment_label": "Neutral"}, {"ticker": "LIDR", "relevance_score": "0.002733", "ticker_sentiment_score": "0.002505", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGLB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.057288", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALLR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01479", "ticker_sentiment_label": "Neutral"}, {"ticker": "GREEL", "relevance_score": "0.002733", "ticker_sentiment_score": "0.011809", "ticker_sentiment_label": "Neutral"}, {"ticker": "OTRA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000558", "ticker_sentiment_label": "Neutral"}, {"ticker": "COLM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006237", "ticker_sentiment_label": "Neutral"}, {"ticker": "XM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000276", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSTM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.009272", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPNG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007028", "ticker_sentiment_label": "Neutral"}, {"ticker": "EFTR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017277", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003805", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVAH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006874", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.0073", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020156", "ticker_sentiment_label": "Neutral"}, {"ticker": "PALI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005603", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWKS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.018675", "ticker_sentiment_label": "Neutral"}, {"ticker": "COMS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.23752", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TBBK", "relevance_score": "0.013666", "ticker_sentiment_score": "-0.002262", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006014", "ticker_sentiment_label": "Neutral"}, {"ticker": "PETS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.020063", "ticker_sentiment_label": "Neutral"}, {"ticker": "CARA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.017", "ticker_sentiment_label": "Neutral"}, {"ticker": "CDXC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.01275", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCYC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.336826", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "AXDX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010578", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRDX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002879", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTRA", "relevance_score": "0.005467", "ticker_sentiment_score": "0.055874", "ticker_sentiment_label": "Neutral"}, {"ticker": "HITI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.082372", "ticker_sentiment_label": "Neutral"}, {"ticker": "PETQ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.213356", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LOB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000114", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBSE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.030308", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSNL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012338", "ticker_sentiment_label": "Neutral"}, {"ticker": "HYRE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.025703", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMNR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007697", "ticker_sentiment_label": "Neutral"}, {"ticker": "RXRX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004579", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPTX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.027221", "ticker_sentiment_label": "Neutral"}, {"ticker": "CASH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001411", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.007341", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDEX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003273", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMER", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.030723", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020412", "ticker_sentiment_label": "Neutral"}, {"ticker": "FVRR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000575", "ticker_sentiment_label": "Neutral"}, {"ticker": "THMO", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000982", "ticker_sentiment_label": "Neutral"}, {"ticker": "PCOR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010626", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002645", "ticker_sentiment_label": "Neutral"}, {"ticker": "ELAN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.019388", "ticker_sentiment_label": "Neutral"}, {"ticker": "GENE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.240893", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "APVO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000495", "ticker_sentiment_label": "Neutral"}, {"ticker": "EAR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005445", "ticker_sentiment_label": "Neutral"}, {"ticker": "GENI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.030796", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTEC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001647", "ticker_sentiment_label": "Neutral"}, {"ticker": "EPIX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003242", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMIH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002191", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.045238", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOMD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.038477", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMPG", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002797", "ticker_sentiment_label": "Neutral"}, {"ticker": "RRGB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.280251", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BLKB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001232", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.391783", "ticker_sentiment_label": "Bearish"}, {"ticker": "WEN", "relevance_score": "0.0082", "ticker_sentiment_score": "-0.001309", "ticker_sentiment_label": "Neutral"}, {"ticker": "MNPR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002166", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011409", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTGT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000715", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTP", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000289", "ticker_sentiment_label": "Neutral"}, {"ticker": "DOMO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.009802", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGEN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020128", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPGF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.01843", "ticker_sentiment_label": "Neutral"}, {"ticker": "SEMR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011116", "ticker_sentiment_label": "Neutral"}, {"ticker": "VOXX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015744", "ticker_sentiment_label": "Neutral"}, {"ticker": "AOUT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000576", "ticker_sentiment_label": "Neutral"}, {"ticker": "NATR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002942", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPCE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010036", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRPL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006359", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRDA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012079", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNMD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00086", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSWI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005483", "ticker_sentiment_label": "Neutral"}, {"ticker": "SITE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.020431", "ticker_sentiment_label": "Neutral"}, {"ticker": "MLKN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004394", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOTZ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00472", "ticker_sentiment_label": "Neutral"}, {"ticker": "DARE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.05572", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011858", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRVS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.292269", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ETSY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.034284", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00684", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLBY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004989", "ticker_sentiment_label": "Neutral"}, {"ticker": "JYNT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00026", "ticker_sentiment_label": "Neutral"}, {"ticker": "MXCT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.219197", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CPRI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.008358", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSKD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.033578", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNNE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00735", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000205", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZBRA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.178497", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ORTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001855", "ticker_sentiment_label": "Neutral"}, {"ticker": "FROG", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001322", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007702", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUCD", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001374", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAGE", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.279642", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ADAP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.015143", "ticker_sentiment_label": "Neutral"}, {"ticker": "DASH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011593", "ticker_sentiment_label": "Neutral"}, {"ticker": "UEIC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.028225", "ticker_sentiment_label": "Neutral"}, {"ticker": "KVHI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004326", "ticker_sentiment_label": "Neutral"}, {"ticker": "APYX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000334", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMBL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.003913", "ticker_sentiment_label": "Neutral"}, {"ticker": "LILA", "relevance_score": "0.0082", "ticker_sentiment_score": "-0.001145", "ticker_sentiment_label": "Neutral"}, {"ticker": "MTW", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.191057", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EDR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007616", "ticker_sentiment_label": "Neutral"}, {"ticker": "BLNK", "relevance_score": "0.005467", "ticker_sentiment_score": "0.053682", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBLX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.036612", "ticker_sentiment_label": "Neutral"}, {"ticker": "VINO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003554", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBKB", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001143", "ticker_sentiment_label": "Neutral"}, {"ticker": "SUMO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.015375", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNCA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.007141", "ticker_sentiment_label": "Neutral"}, {"ticker": "PRPO", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000252", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNLI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.00079", "ticker_sentiment_label": "Neutral"}, {"ticker": "CORZ", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.008964", "ticker_sentiment_label": "Neutral"}, {"ticker": "FTRP", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000741", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLLS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012085", "ticker_sentiment_label": "Neutral"}, {"ticker": "BEAM", "relevance_score": "0.005467", "ticker_sentiment_score": "0.001698", "ticker_sentiment_label": "Neutral"}, {"ticker": "KYMR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.012988", "ticker_sentiment_label": "Neutral"}, {"ticker": "JJSF", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.05471", "ticker_sentiment_label": "Neutral"}, {"ticker": "AYLA", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000877", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.00683", "ticker_sentiment_label": "Neutral"}, {"ticker": "TLYS", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.004935", "ticker_sentiment_label": "Neutral"}, {"ticker": "WEBR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.126513", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAMI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.000836", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIND", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.033769", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADBE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.012161", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALRM", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.006295", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOEV", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.002734", "ticker_sentiment_label": "Neutral"}, {"ticker": "TACT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011746", "ticker_sentiment_label": "Neutral"}, {"ticker": "KLTR", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002102", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASAN", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.018369", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPRX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011543", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRAR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.464763", "ticker_sentiment_label": "Bearish"}, {"ticker": "WIX", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.010525", "ticker_sentiment_label": "Neutral"}, {"ticker": "DDI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006221", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004222", "ticker_sentiment_label": "Neutral"}, {"ticker": "GLBE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.000752", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.316405", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LTCH", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003242", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002004", "ticker_sentiment_label": "Neutral"}, {"ticker": "JELD", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002491", "ticker_sentiment_label": "Neutral"}, {"ticker": "TDC", "relevance_score": "0.005467", "ticker_sentiment_score": "0.002169", "ticker_sentiment_label": "Neutral"}, {"ticker": "SBH", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.005907", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.005467", "ticker_sentiment_score": "0.003344", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTEX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.066118", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNCE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.0198", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRAY", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004344", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBER", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001654", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRHC", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001238", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTV", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010854", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDIMF", "relevance_score": "0.002733", "ticker_sentiment_score": "-0.006894", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSTX", "relevance_score": "0.005467", "ticker_sentiment_score": "0.014495", "ticker_sentiment_label": "Neutral"}, {"ticker": "RMBL", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.011586", "ticker_sentiment_label": "Neutral"}, {"ticker": "NYT", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.030689", "ticker_sentiment_label": "Neutral"}, {"ticker": "LEDS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.011337", "ticker_sentiment_label": "Neutral"}, {"ticker": "WDAY", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.013645", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.004338", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRPT", "relevance_score": "0.005467", "ticker_sentiment_score": "0.006837", "ticker_sentiment_label": "Neutral"}, {"ticker": "CMPS", "relevance_score": "0.005467", "ticker_sentiment_score": "0.032635", "ticker_sentiment_label": "Neutral"}, {"ticker": "NWBI", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.001855", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTR", "relevance_score": "0.005467", "ticker_sentiment_score": "-0.287692", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SGTX", "relevance_score": "0.005467", "ticker_sentiment_score": "6e-06", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNE", "relevance_score": "0.005467", "ticker_sentiment_score": "0.010302", "ticker_sentiment_label": "Neutral"}, {"ticker": "HAIN", "relevance_score": "0.005467", "ticker_sentiment_score": "0.014747", "ticker_sentiment_label": "Neutral"}, {"ticker": "RPID", "relevance_score": "0.005467", "ticker_sentiment_score": "0.039922", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:BGN", "relevance_score": "0.002733", "ticker_sentiment_score": "0.009564", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict", "url": "https://www.benzinga.com/general/biotech/22/03/26367702/the-daily-biotech-pulse-roches-lung-cancer-combo-therapy-flunks-late-stage-study-adagio-spikes-on", "time_published": "20220330T114641", "authors": ["Shanthi Rexaline"], "summary": "Here's a roundup of top developments in the biotech space over the last 24 hours.\nStocks In Focus\nJ&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents\nJohnson & Johnson's  ( NYSE: JNJ )  Janssen unit said the U.S. Food and Drug Administration has approved Caben", "banner_image": "https://cdn.benzinga.com/files/images/story/2012/lab-5740505_1920_14.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": -0.004968, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AFMD", "relevance_score": "0.087744", "ticker_sentiment_score": "-0.000942", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.087744", "ticker_sentiment_score": "-0.031831", "ticker_sentiment_label": "Neutral"}, {"ticker": "IGMS", "relevance_score": "0.087744", "ticker_sentiment_score": "0.000491", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDSB", "relevance_score": "0.087744", "ticker_sentiment_score": "0.000481", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.087744", "ticker_sentiment_score": "0.012517", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNOA", "relevance_score": "0.087744", "ticker_sentiment_score": "0.002103", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALA", "relevance_score": "0.174429", "ticker_sentiment_score": "-0.001664", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.087744", "ticker_sentiment_score": "0.024836", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKT", "relevance_score": "0.087744", "ticker_sentiment_score": "0.000973", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADMP", "relevance_score": "0.087744", "ticker_sentiment_score": "0.003177", "ticker_sentiment_label": "Neutral"}, {"ticker": "GERN", "relevance_score": "0.087744", "ticker_sentiment_score": "0.003831", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVO", "relevance_score": "0.087744", "ticker_sentiment_score": "0.000746", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.087744", "ticker_sentiment_score": "0.043271", "ticker_sentiment_label": "Neutral"}, {"ticker": "GSK", "relevance_score": "0.087744", "ticker_sentiment_score": "0.024836", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGIOF", "relevance_score": "0.043938", "ticker_sentiment_score": "0.024836", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.087744", "ticker_sentiment_score": "0.060911", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSHA", "relevance_score": "0.087744", "ticker_sentiment_score": "0.000243", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies", "url": "https://www.benzinga.com/pressreleases/22/03/g26367562/replimune-provides-new-clinical-data-broad-program-update-and-future-development-strategy-for-its-", "time_published": "20220330T110000", "authors": ["Globe Newswire"], "summary": "RP1 combined with Opdivo\u00ae  ( nivolumab )  continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers  ( NMSC ) ; new positive initial data in patients with anti-PD1 failed NMSC\nInitial data shows clinical activity with RP1 monotherapy in solid organ t", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.124782, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.114286", "ticker_sentiment_score": "0.152853", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BMY", "relevance_score": "0.028664", "ticker_sentiment_score": "0.011514", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014334", "ticker_sentiment_score": "0.002118", "ticker_sentiment_label": "Neutral"}]}, {"title": "Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies", "url": "https://www.globenewswire.com/news-release/2022/03/30/2412692/0/en/Replimune-Provides-New-Clinical-Data-Broad-Program-Update-and-Future-Development-Strategy-for-its-Tumor-Directed-Oncolytic-Immunotherapies.html", "time_published": "20220330T110000", "authors": ["Replimune Group Inc"], "summary": "RP1 combined with Opdivo\u00ae  ( nivolumab )  continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers  ( NMSC ) ; new positive initial data in patients with anti-PD1 failed NMSC", "banner_image": "", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.122767, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "REPL", "relevance_score": "0.101416", "ticker_sentiment_score": "0.142525", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.04356", "ticker_sentiment_score": "0.0116", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNY", "relevance_score": "0.014526", "ticker_sentiment_score": "0.00335", "ticker_sentiment_label": "Neutral"}]}, {"title": "The Week Ahead In Biotech  ( March 27-April 2 ) : Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More", "url": "https://www.benzinga.com/general/biotech/22/03/26313832/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-fo", "time_published": "20220327T204003", "authors": ["Shanthi Rexaline"], "summary": "Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.\nAmong noteworthy developments in the space, Novartis AG  ( NYSE: NVS )  announced the FDA nod for its radioligand therapy Pluvicto for met", "banner_image": "https://cdn.benzinga.com/files/images/story/2012/biotech_6.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.017554, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PTE", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000501", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNTG", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000936", "ticker_sentiment_label": "Neutral"}, {"ticker": "NDRA", "relevance_score": "0.074856", "ticker_sentiment_score": "0.006143", "ticker_sentiment_label": "Neutral"}, {"ticker": "ORTX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000489", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUMA", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.000995", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITRM", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.003418", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATAI", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000916", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLAR", "relevance_score": "0.037469", "ticker_sentiment_score": "-0.038847", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYCC", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000436", "ticker_sentiment_label": "Neutral"}, {"ticker": "REPL", "relevance_score": "0.074856", "ticker_sentiment_score": "0.020218", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCYX", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.000428", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.074856", "ticker_sentiment_score": "0.061292", "ticker_sentiment_label": "Neutral"}, {"ticker": "CALA", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.014185", "ticker_sentiment_label": "Neutral"}, {"ticker": "LPCN", "relevance_score": "0.149054", "ticker_sentiment_score": "-0.023035", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001122", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTGM", "relevance_score": "0.074856", "ticker_sentiment_score": "0.00114", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRT", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000335", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADMP", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001224", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEIP", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.22419", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NBRV", "relevance_score": "0.074856", "ticker_sentiment_score": "0.006913", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSHA", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000243", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFIB", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.005342", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALDX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.035924", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCDA", "relevance_score": "0.074856", "ticker_sentiment_score": "0.003611", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCLI", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000798", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFMD", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.000942", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMMP", "relevance_score": "0.074856", "ticker_sentiment_score": "0.038917", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001447", "ticker_sentiment_label": "Neutral"}, {"ticker": "PDSB", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000481", "ticker_sentiment_label": "Neutral"}, {"ticker": "KALA", "relevance_score": "0.074856", "ticker_sentiment_score": "3e-06", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRS", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.038847", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDAP", "relevance_score": "0.074856", "ticker_sentiment_score": "-3e-05", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVLP", "relevance_score": "0.074856", "ticker_sentiment_score": "0.003282", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.002725", "ticker_sentiment_label": "Neutral"}, {"ticker": "LXRX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001077", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGRX", "relevance_score": "0.074856", "ticker_sentiment_score": "0.057955", "ticker_sentiment_label": "Neutral"}, {"ticker": "AXLA", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001652", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTK", "relevance_score": "0.074856", "ticker_sentiment_score": "0.003712", "ticker_sentiment_label": "Neutral"}, {"ticker": "IKT", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000973", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRXT", "relevance_score": "0.037469", "ticker_sentiment_score": "-0.038847", "ticker_sentiment_label": "Neutral"}, {"ticker": "AKBA", "relevance_score": "0.074856", "ticker_sentiment_score": "0.000493", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVO", "relevance_score": "0.074856", "ticker_sentiment_score": "0.001099", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPRO", "relevance_score": "0.074856", "ticker_sentiment_score": "0.043271", "ticker_sentiment_label": "Neutral"}, {"ticker": "ICVX", "relevance_score": "0.074856", "ticker_sentiment_score": "-0.22419", "ticker_sentiment_label": "Somewhat-Bearish"}]}]}